



LUND UNIVERSITY

Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. From antibody response to memory cells.

Nived, Per

2021

Document Version:

Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Nived, P. (2021). *Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. From antibody response to memory cells.* [Doctoral Thesis (compilation), Department of Clinical Sciences, Lund]. Lund University, Faculty of Medicine.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients

From antibody response to memory cells

PER NIVED

DEPARTMENT OF CLINICAL SCIENCES, LUND | LUND UNIVERSITY



Pneumococcal vaccination in inflammatory rheumatic
disease and in splenectomy patients

Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients

From antibody response to memory cells

Per Nived



LUND
UNIVERSITY

DOCTORAL DISSERTATION

by due permission of the Faculty of Medicine, Lund University, Sweden.

To be defended at Lottasalen, the Lecture Hall of the Department of
Rheumatology, Skåne University Hospital in Lund, on May 6th at 13.00.

Faculty opponent

Professor Vanda Friman, Department of Infectious Diseases, Sahlgrenska
University Hospital, University of Gothenburg

Organization LUND UNIVERSITY	Document name Doctoral dissertation	
	Date of issue April 8th 2021	
Author: Per Nived	Sponsoring organization	
Title and subtitle: Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. - From antibody response to memory cells		
<p>Abstract</p> <p>Objectives:</p> <p>The overall aim of the dissertation is to examine antibody response to immunization with pneumococcal vaccine in patients with inflammatory rheumatic disease (IRD), in relation to disease-modifying antirheumatic drug (DMARD) treatments, and in postsplenectomy patients.</p> <p>Methods:</p> <p>(I) Splenectomized patients without previous pneumococcal conjugate vaccine (PCV) immunization were invited to receive one dose 13-valent PCV (PCV13). Blood was drawn before and 4-6 weeks after PCV13. Serotype-specific antibody responses were determined using a multiplex fluorescent microsphere immunoassay (MFI). (II and III) Consecutive patients with systemic vasculitis, rheumatoid arthritis (RA), and primary Sjögren's syndrome (pSS), and healthy controls (HC) were invited to receive immunization with one dose PCV13. Serotype 6B and 23F IgG were determined before and 4-6 weeks after PCV13 using enzyme-linked immunosorbent assay (ELISA) and functionality of antibodies (23F) with an opsonophagocytic activity (OPA) assay. Positive antibody response (AR) was defined as ≥ 2-fold rise in pre- to postvaccination IgG. (IV) Patients with RA or systemic vasculitis and HC were invited to receive PCV and a booster dose with 23-valent pneumococcal polysaccharide vaccine (PCV23) after at least 8 weeks. IgG was determined before PCV and PPV23 and 4-6 weeks after using MFI and OPA assay. (V) RA patients planned to start methotrexate (MTX) treatment, patients without DMARD and HC were included. Blood was obtained at inclusion, at immunization with PCV13 (after at least 6 weeks on MTX) and 7 days after for flow cytometric phenotyping of lymphocytes, and 4-6 weeks after for MFI.</p> <p>Results:</p> <p>Splenectomy patients (n=24) with previous PPV23, received a dose of PCV13, and geometric mean concentration (GMC) increased for 9/12 serotypes. Patients with systemic vasculitis (n=49) and ongoing standard of care therapy received one dose of PCV13, IgG GMC for serotypes 6B and 23F increased, and there was no significant difference in antibody response (≥ 2-fold rise in IgG) compared to HC. Although OPA increased after PCV13, it was lower in patients compared to HC ($p=0.001$). In patients with RA (n=50) and pSS (n=15) without ongoing DMARD treatment IgG GMC for 6B and 23F and OPA increased, and the proportions with positive antibody responses for RA (52%) were similar to HC (55%, n=49). Patients with IRD treated with rituximab (RTX, n=30), abatacept (n=23), conventional DMARD (cDMARD, n=27) and HC (n=28) received immunization with PCV+PPV23. Antibody response improved after PPV23 in cDMARD (both 2-fold AR and OPA), and ABT (2-fold AR but not OPA), but no improvement was seen in RTX treated patients. Start of MTX treatment in RA patients resulted in decreased Th17 cells, and impaired memory B cell and plasmablast responses after PCV13.</p> <p>Conclusions:</p> <p>PCV is immunogenic as a booster dose in splenectomized patients with previous PPV23 immunization. PCV is immunogenic in systemic vasculitis patients with ongoing standard of care treatment, although functionality is lower compared to HC. Antibody response is not impaired in RA and pSS patients without DMARD treatment compared to HC. A PPV23 booster could be recommended in IRD patients with cDMARD, and ABT, but vaccination needs to be completed before starting RTX. MTX treatment can have negative effects on memory B cells following PCV13.</p>		
Key words: inflammatory rheumatic disease, pneumococcal conjugated vaccine, pneumococcal polysaccharide vaccine, antibody response, memory cells, splenectomy		
Classification system and/or index terms (if any)		
Supplementary bibliographical information		Language: English, Swedish
ISSN and key title: 1652-8220 Pneumococcal vaccination in IRD and after splenectomy		ISBN: 978-91-8021-042-3
Recipient's notes	Number of pages: 97	Price
	Security classification	

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature



Date 2021-03-23

Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients

From antibody response to memory cells

Per Nived



LUND
UNIVERSITY

Coverphoto by MiaZola

Copyright pp 1-97 Per Nived

Paper 1 © Elsevier

Paper 2 © Elsevier

Paper 3 © BioMed Central Ltd.

Paper 4 © BioMed Central Ltd.

Paper 5 © by the Authors (Manuscript unpublished)

Faculty of Medicine

Department of Clinical Sciences Lund, Section of Rheumatology

ISBN 978-91-8021-042-3

ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University
Lund 2021



Media-Tryck is a Nordic Swan Ecolabel certified provider of printed material. Read more about our environmental work at www.mediatryck.lu.se

MADE IN SWEDEN 

Till Aleksandra, Alice, Ella, Mira och Vera

Table of Contents

List of papers.....	10
Abbreviations	11
Populärvetenskaplig sammanfattning.....	13
Introduction	17
Pneumococcal disease.....	19
<i>Streptococcus pneumoniae</i>	19
Immune response to pneumococcal infection	20
Risk factors for invasive pneumococcal disease	21
Pneumococcal vaccination	23
Vaccine immunology	23
Principal differences in the immune response to pneumococcal conjugate compared to polysaccharide vaccines	26
Efficacy	26
Epidemiology of IPD in the era of PCV.....	27
Combination of PCV13 and PPV23.....	27
Measuring antibody response to pneumococcal vaccines.....	28
Autoimmune inflammatory rheumatic disease.....	31
Rheumatoid arthritis.....	31
Systemic vasculitis	34
Primary Sjögren’s syndrome.....	36
Antirheumatic treatment.....	36
Aims	43
Patients and methods	45
Patient inclusion and pneumococcal immunization	45
Pneumococcal serology.....	47
Phenotyping of lymphocytes with flow cytometry	49
Statistical methods.....	50

Results.....	51
Splenectomy patients (paper I).....	51
Systemic vasculitis patients (paper II).....	53
Patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment (paper III)	57
Prime-boost vaccination strategy in patients receiving conventional DMARDs, abatacept and rituximab (paper IV)	59
Methotrexate reduced Th17 cells and impaired plasmablast and memory B cell responses after PCV immunization in RA patients (paper V).....	67
Discussion	73
Post splenectomy patients	73
Systemic vasculitis patients receiving standard of care therapy	74
Patients with RA or primary Sjögren’s syndrome patients without DMARD treatment.....	75
Prime-boost pneumococcal vaccination in relation to rituximab, abatacept and cDMARD	75
Strengths and limitations with the pneumococcal serological assays	76
Methotrexate reduced circulating Th17 cells and impaired memory B cell and plasmablast responses after immunization	77
Future perspectives.....	78
Tack	81
References	83

List of papers

- I. **Nived P**, Jørgensen CS, Settergren B. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals. *Vaccine*. 2015;33(14):1688–94.
- II. **Nived P**, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. *Vaccine*. 2017;35(29):3639–46.
- III. **Nived P**, Saxne T, Geborek P, Mandl T, Skattum L, Kapetanovic MC. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment. *BMC Rheumatol*. 2018;2:12.
- IV. **Nived P**, Jonsson G, Settergren B, Einarsson J, Olofsson T, Jorgensen CS, Skattum L, Kapetanovic MC. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. *Arthritis Res Ther*. 2020;22(1):36.
- V. **Nived P**, Pettersson Å, Jönsson G, Bengtsson A, Settergren B, Skattum L, Johansson Å, Kapetanovic MC. Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients. Submitted manuscript under revision.

The articles are reprinted with permission from the publishers.

Abbreviations

AAV	ANCA-associated vasculitis
ABT	Abatacept
ANCA	Anti-neutrophil cytoplasmic antibody
Anti-CCP	Antibodies against cyclic-citrullinated peptides
ARR	Antibody response ratio
AZA	Azathioprine
CD	Cluster of differentiation
cmTfh	Circulating memory T follicular helper
CYC	Cyclophosphamide
CXCR	C-X-C motif chemokine receptor
DAS28	28-joint disease activity score
DMARD	Disease-modifying antirheumatic drug
ELISA	Enzyme-linked immunosorbent assay
GC	Germinal center
GMC	Geometric mean concentration
HC	Healthy controls
ICOS	Inducible T cell costimulatory
Ig	Immunoglobulin
IL	Interleukin
IPD	Invasive pneumococcal disease
Mabs	Monoclonal antibodies
MFMI	Multiplex fluorescent microsphere immunoassay
MHC	Major histocompatibility complex
MMFt	Mycophenolate mofetil
MTX	Methotrexate
MZ	Marginal zone
OPA	Opsonophagocytic activity

OPSI	Overwhelming postsplenectomy infection
PCV	Pneumococcal conjugate vaccine
PD-1	Programmed cell death protein 1
PPV23	23-valent pneumococcal polysaccharide vaccine
pSS	Primary Sjögren's syndrome
RA	Rheumatoid arthritis
RF	Rheumatoid factor
RTX	Rituximab
TCR	T cell receptor
TD	T cell dependent
Th	T helper
Tfh	T follicular helper
TI	T cell independent
Treg	T regulatory

Populärvetenskaplig sammanfattning

Bakgrund

Reumatoid artrit (RA) och andra inflammatoriska reumatiska sjukdomar är förenade med en ökad risk för allvarliga infektioner. Den förhöjda infektionsrisken beror dels på sjukdomen i sig, samsjuklighet såsom hjärt- eller lungsjukdom, och till sist kan den vara en följd av den antireumatiska behandlingen. Behandlingen som syftar till att dämpa inflammationsaktiviteten, förbättra livskvaliteten och på sikt minska skador och förbättra överlevnaden för patienten, kan också innebära ett nedsatt immunförsvar med ökad mottaglighet för infektioner. En stor andel av dessa infektioner utgörs av lunginflammationer, och inom denna grupp är infektioner orsakade av pneumokockbakterier vanligast. Pneumokocker är också den vanligaste orsaken till allvarlig hjärnhinneinflammation, öroninflammation och bihåleinflammation men kan även orsaka blodförgiftning, infektioner i leder, skelett m.m. Även personer som till följd av skador eller sjukdom behövt operera bort mjälten löper ökad risk för pneumokockinfektioner.

Pneumokocker omges av en kolhydratkapsel, och denna utgör bakteriens viktigaste skyddsmekanism för att undkomma att bli upptäckt och omhändertagen av kroppens immunförsvar. Pneumokockinfektioner kan potentiellt förebyggas genom vaccination. Det finns i dagsläget två olika typer av pneumokockvacciner. Det äldre vaccinet Pneumovax[®] består av kolhydrater och skyddar mot 23 vanliga typer av pneumokocker. I det modernare vaccinet Prevenar 13[®] har kolhydrater från 13 pneumokocktyper på kemisk väg bundits till ett bärarprotein. Troligen leder det till en ökad stimulering av immunförsvarets T-celler med bildning av minnesceller och förhoppningen är att det ger ett mer långvarigt skydd mot pneumokockinfektioner. Prevenar 13[®] har en skyddseffekt på ca 75 % mot allvarliga pneumokockinfektioner (orsakade av vaccintyper) hos äldre personer. Liknande resultat har tidigare visats i studier av Pneumovax[®]. På senare år rekommenderas patienter med nedsatt immunförsvar att vaccineras med en kombination av Prevenar 13[®] och en dos Pneumovax[®] efter minst 8 veckor.

Det övergripande syftet med denna avhandling var att undersöka effekten av pneumokockvaccin på immunförsvarets antikroppar vid inflammatorisk reumatisk sjukdom och till patienter som opererat bort mjälten.

Pneumokockvaccination vid avsaknad av mjälte

Patienter som opererat bort mjälten, bjöds in till att delta i en studie av tidigare vaccinationer och vaccinerades med Prevenar 13[®] om de inte fått det tidigare. Det visade sig att de flesta av patienterna hade fått pneumokockvaccin (81 %), men betydligt färre var vaccinerade mot s.k. meningokocker (23 %). Patienter som

tidigare fått Pneumovax[®], vaccinerades i studien med en dos Prevenar 13[®] och antikroppssvar analyserades. Relativt höga nivåer av antikroppar sågs redan vid inklusion i studien (efter tidigare Pneumovax[®]), och Prevenar 13[®] hade en förstärkande effekt på immunförsvarets antikroppar. Resultatet innebär att patienter som opererat bort mjälten och tidigare fått grundvaccination med Pneumovax[®], kan ha nytta av att rekommenderas vaccination med Prevenar 13[®] som en påfyllnadsdos. Patienter som grundvaccineras idag bör dock få Prevenar 13[®] först och följt av en dos Pneumovax[®].

Pneumokockvaccination vid reumatiska sjukdomar

I en andra delstudie av patienter med inflammatorisk kärlsjukdom (vaskulit) under uppföljning vid reumamottagning, genomfördes vaccination med Prevenar 13[®] under pågående inflammationsdämpande behandling. Antikroppssvaret hos dessa patienter jämfördes med svaret hos en grupp av friska försökspersoner efter en dos av samma vaccin. Vaccination visade sig leda till en stegring av antikroppar som nästan var i nivå med kontrollerna men immuncellers upptag av pneumokocker (s.k. opsonofagocytos) var nedsatt. Det innebär att patienter med vaskulit som behöver inleda behandling tidigt, kan vaccineras och få effekt mot pneumokocker trots immundämpande behandling.

I en tredje delstudie inkluderades patienter med RA och patienter med s.k. primärt Sjögrens syndrom (pSS) som inte hade någon aktiv antireumatisk behandling. I studien fanns även en mindre grupp av RA patienter behandlade med methotrexate (MTX, den vanligaste antireumatiska medicinen) samt friska kontroller. Alla vaccinerades med en dos Prevenar 13[®]. Det visade sig att antikroppssvar vid RA och pSS är i samma nivå som hos friska kontroller även om opsonofagocytos var något nedsatt. Patienter med MTX uppvisade i likhet med tidigare studier ett tydligt nedsatt antikroppssvar efter vaccination. Det innebär att det är mycket viktigt att patienter vaccineras innan de påbörjar antireumatisk behandling.

I delstudie fyra jämfördes antikroppssvaret efter en dos Prevenar 13[®] med svaret efter påfyllnad (boosting) med en dos Pneumovax[®] hos patienter med reumatisk sjukdom och friska kontroller. Det fanns tre grupper av antireumatisk behandling: (1) B-cellshämmande rituximab, (2) T-cellshämmande abatacept och (3) konventionell antireumatisk behandling (MTX m.fl.). Patienter med rituximab uppvisade mycket nedsatt antikroppssvar efter Prevenar 13[®], och en dos Pneumovax[®] förbättrade inte detta. Patienter med abatacept svarade något bättre på Prevenar 13[®] och det sågs en liten tilläggs effekt av Pneumovax[®]. Däremot sågs tydlig förbättring av antikroppssvar, hos patienter med konventionella antireumatiska mediciner (MTX m.fl.), när de vaccinerades med Prevenar 13[®] följt av Pneumovax[®], jämfört med bara en dos Prevenar 13[®]. Studien understryker vikten av att RA patienter vaccineras före start av den kraftigt B-cellshämmande medicinen

rituximab. RA patienter som behandlas med MTX, och tidigare fått en dos Prevenar 13[®], kan ha nytta av en påfyllningsdos Pneumovax[®].

Immunceller vid RA, effekt av MTX och pneumokockvaccination

Syftet med den femte studien var att undersöka effekten av MTX på immunförsvarets B och T celler, och effekt av immunstimulering med konjugerat pneumokockvaccin. Detta för att förstå mer om mekanismerna bakom den välkända effekten av MTX att minska antikroppssvar efter pneumokockvaccin. I studien inkluderades patienter med RA som planerades att påbörja behandling med MTX, RA patienter utan behandling och friska kontroller. Immunsystemets B- och T-celler analyserades i blodet vid olika tidpunkter. Alla vaccinerades med en dos Prevenar 13[®], men RA patienter som startade med MTX fick vänta minst 6 veckor för att behandlingen skulle börja verka före vaccination. Efter start av behandling med MTX sågs en minskning av s.k. T-hjälparceller 17. Efter vaccination av RA patienter utan behandling och kontroller sågs tydliga ökningar av förstadier till antikroppsbyggande celler (plasmablast) och minnes-B-celler. Dessa ökningar uteblev hos patienter med MTX. Vi tolkar det som att MTX har effekter på både T celler och B celler, vilket kan få negativa effekter på det immunologiska minnet, dvs den långvariga skyddseffekten mot pneumokockinfektioner.

Introduction

The history of vaccination begins in 16th century China with the practice of variolisation, i.e. the inoculation of human smallpox material to prevent disease (1). In 1796, British physician Edward Jenner conducted a famous experiment based on the observation that milkmaids previously exposed to the mild cowpox disease were protected against smallpox (2). With an arm-to-arm transfer technique, he inoculated cowpox material, thus introducing the concept of live attenuated vaccination. About 80 years later, Louis Pasteur developed methods to attenuate microorganisms in his Paris laboratory, and the work resulted in the first human rabies virus vaccine (3).

In 1881, Pasteur, and George Sternberg in the United States, independently discovered the pneumococcus, and both described its surrounding capsule (4). Three years later, Hans Christian Gram while examining deceased pneumonia patients, developed a technique, known as Gram staining, to differentiate the Gram-positive pneumococci from Gram-negative *Klebsiella pneumoniae*. Sir Almroth Wright conducted the first trial with a killed pneumococci vaccine in South African gold miners in 1910, but subsequent analysis questioned its efficacy (4). The presence of distinct pneumococcal serotypes was first demonstrated by Neufeld and Händel in 1910, and in 1917, Avery reported that pneumococcal capsules were composed of polysaccharide (4). In 1927, Schiemann and Casper described the immunogenicity of pneumococcal polysaccharides in mice (5), and in 1930, Francis and Tillett reported similar immune responses in humans (6). During a pneumonia epidemic in the military in 1945, recruits were either immunized with capsular polysaccharides of serotypes 1, 2, 5 and 7, or saline, and Macleod and Heidelberger reported that this 4-valent vaccine was efficacious in the prevention of pneumococcal pneumonia (7). Alexander Fleming's discovery of penicillin and its efficacy in the treatment of pneumococcal infections led to a decline in the field of pneumococcal serotyping and vaccine development. In the 1970s, Eli Lilly & Co and Merck & Co conducted a trials of polyvalent pneumococcal polysaccharide vaccines (PPVs) in South Africa, with around 80% efficacy in the prevention of vaccine-type pneumococcal infection and bacteremia (4). Merck & Co licensed a 14-valent PPV in 1977, and the 23-valent vaccine (PPV23, Pneumovax®) followed in 1983. PPV23 was formulated to cover 90% of serotypes causing IPD worldwide at the time (8).

In recent years, worldwide measles vaccine coverage has reached 85% (9), and conversely, the annual number of deaths from measles has decreased from an

estimated 2.6 million in 1963, to 110,000 in 2017. However, the most notable success story in the history of vaccination was the eradication of smallpox disease in the late 1970s, through large immunization campaigns coordinated by the World Health Organization (WHO). Child immunization with 7-valent protein-conjugate pneumococcal vaccine (PCV7) was introduced in the United States in 2000, and it was followed by a great reduction of pneumococcal disease in young children. Through herd immunity, pneumococcal disease rates decreased in the elderly population (10). 13-valent pneumococcal conjugate vaccine (PCV13) was licensed late in 2011, and has further reduced pneumococcal disease, but continued serotype replacement with emerging infections of non-vaccine type is a great problem. The immunocompromised population is growing, e.g. more patients undergo life-saving transplantations, and others are getting efficient treatments for debilitating chronic inflammatory disease. The immunocompromised are at risk of severe pneumococcal infections, but knowledge regarding pneumococcal vaccine immunogenicity, efficacy, and safety in this populations is scarce.

Pneumococcal disease

The bacterial pathogen *Streptococcus pneumoniae* (the pneumococcus) has a high invasive potential. Pneumococcal disease is the leading cause of mortality among infectious diseases worldwide. On the other hand, pneumococci are frequent colonizers of the upper airways in up to 60% of asymptomatic small children (11). The pneumococcus attaches to the nasopharyngeal epithelium, and from there it can spread locally causing sinusitis or otitis, aspiration of the bacteria may lead to pneumonia, and invasion of the blood stream or blood-brain barrier leads to septicaemia or meningitis. Invasive pneumococcal disease (IPD) is defined by the isolation of pneumococci from a normally sterile bodily compartment, such as blood or cerebrospinal fluid. Before the introduction of penicillin, the mortality associated with pneumococcal pneumonia, bacteraemia and meningitis was 20%, 50%, and 80-100%, respectively. With modern antibiotic treatment and intensive care, the mortality rates of pneumococcal disease have improved to 5% in pneumonia, 20% in bacteraemia, and 30% in meningitis (12, 13).

Streptococcus pneumoniae

Microbiology

The genus streptococcus consists of Gram-positive coccoid shaped bacteria that are catalase-negative, facultative anaerobes, and grow in pairs or chains. They grow optimally on blood agar, a source of catalase, and can be further classified based on their ability to cause lysis of red blood cells (14). On blood agar, colonies of *S.pyogenes*, the archetypal β -hemolytic streptococci, are surrounded by a clear zone of hemolysis. In contrast, the green discoloration around *S. pneumoniae* colonies, classically termed α -hemolysis, is caused by oxidation of haemoglobin to methemoglobin, and the red blood cell membranes are left intact. Pneumococci characteristically arrange in pairs, as diplococci. The bacteriological identification of pneumococci, and differentiation from other α -hemolytic commensal (viridans) streptococci, requires two additional reactions: growth inhibition by ethyl hydrocupreine (Optochin) and finally solubility in bile (15).

Cellular anatomy.

Outside the pneumococcal cytoplasmic membrane is the cell wall, which surrounds a thin periplasmic space. The main building blocks of the cell wall are the polymeric carbohydrates peptidoglycan and teichoic acid. Teichoic acid covalently linked to peptidoglycan on the surface of the cell wall constitutes the C-polysaccharide (15). The polysaccharide capsule has covalent links to peptidoglycan and C-polysaccharide, and it covers the external surface of the pneumococcus.

Virulence factors

The capsular polysaccharide is the pneumococcus' most important virulence factor, because it inhibits complement binding and phagocytosis, unless anticapsular antibody is present. So far, 97 capsular serotypes have been described (16). The serotypes are numbered, and similar polysaccharide structures are grouped together, e.g. 6A, 6B and 6C. Although almost all clinical isolates of pneumococci are encapsulated strains, non-encapsulated strains have been described as cause of both non-invasive (mainly in outbreaks of conjunctivitis) and rarely invasive disease (17). The binding of anticapsular antibodies leads to swelling of the capsule, the quellung reaction, which enables microscopic visualization of the pneumococcal capsule (18).

Pneumococci produce pneumolysin, which is cytotoxic for phagocytes and respiratory epithelial cells, and proinflammatory by activating complement and inducing tumor necrosis factor- α and interleukin-1 (15).

Autolysin cuts the peptidoglycan cross-links of the cell wall, resulting in autolysis of the pneumococcus, release of pneumolysin and other cell components and subsequent tissue inflammation.

Pneumococcal surface protein A (PspA) inhibit phagocytosis by blocking deposition and activation of complement.

Choline-binding protein A (CbpA) can bind to the epithelium of both the nasopharynx and the blood-brain barrier, facilitating invasion of the blood stream or central nervous system.

Immune response to pneumococcal infection

Pneumococci are poorly opsonized bacteria, and in the natural course of pneumococcal infection, the resolution of fever after 5-8 days is accompanied by the appearance of anti-capsular antibody (15). Anti-capsular antibody greatly increases phagocytosis and killing of pneumococci in vitro (19).

Pneumococcal antibody levels increase with age and inversely the incidence of IPD decreases, except for the elderly, although antibody levels remain high in the population above age 65 years they are at an increased risk of IPD (20).

Role of the spleen in the immune response to pneumococcal infection

Unopsonized pneumococci in the circulation are mainly cleared by the spleen (21). The marginal zone is located between the erythrocyte-rich red pulp and the lymphocyte-dominated white pulp of the spleen. The marginal zone contains a unique population of memory B cells which produce natural immunoglobulin M (IgM) antibodies against encapsulated bacteria, such as pneumococci (22). Marginal zone (MZ) B cells are reduced in young children (<2 years), patients with common variable immunodeficiency (CVID), human immunodeficiency virus (HIV) infection, asplenia, and elderly people (22).

Risk factors for invasive pneumococcal disease

Populations with impaired antibody responses, such as infants, elderly, bone marrow transplant recipients, and patients with hypogammaglobulinemia are at increased risks of serious pneumococcal infections (23). Before the introduction of pneumococcal conjugate vaccine (PCV) in child immunization programs, the highest incidence of IPD was observed in children under age 5 years (24). In the PCV era, peak IPD incidence has shifted to the elderly population, above age 65 years, and a smaller peak is seen in young children (25).

Patients with chronic respiratory disease, chronic heart failure, and smokers are at increased risks of pneumococcal pneumonia and IPD (26). The risk of IPD is also increased in diseases with interference in the function of polymorphonuclear phagocytes, such as diabetes mellitus, chronic renal disease and cirrhosis of the liver (23).

Immunocompromised patients are at increased risk of pneumococcal disease, mainly because of impaired abilities to generate antibodies to new antigens (23). In a meta-analysis, the pooled incidence of IPD was 318-331/100,000 person years in HIV patients, 812/100,000 person years following allogeneic stem cell transplant, and 465/100,000 in solid organ transplant recipients (27), compared to 10/100,000 person years in healthy controls. Based on few studies, and relatively small samples sizes, pooled incidence of IPD was 65/100,000 person years in patients with chronic inflammatory disease. Retrospective cohort studies of IPD in England have demonstrated increased rates of IPD in patients with rheumatoid arthritis (RA, incidence rate ratio [IRR] 2.5), systemic sclerosis (SSc, IRR 4.2) and systemic lupus erythematosus (SLE, IRR 5.0) (28). In a Swedish retrospective cohort study, IRR

was 4.9 for RA and 14.2 for SLE patients (29). Hematologic malignancies are associated with high risks of IPD, especially multiple myeloma (29, 30).

Asplenia or hyposplenic states

Functional or anatomical asplenia are well-known risk factors for pneumococcal disease. Splenectomy causes a substantial reduction in numbers of circulating MZ IgM⁺CD27⁺ memory B cells, which are important in the defence against encapsulated bacteria (22). Overwhelming post-splenectomy infection (OPSI) is characterized by fulminant sepsis, pneumonia or meningitis after surgical removal of the spleen (22). The classic causes of OPSI from the prevaccination era, are encapsulated bacteria such as pneumococcus (50-90%), *Haemophilus influenzae* type B, or *Neisseria meningitidis* (22). Other important pathogens are *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter jejuni*, *Cryptosporidium parvum*, *Babesia microti* and malaria in endemic areas (31). The reported mortality in OPSI is high, 50-70% (32), although no studies have addressed this question in the recent years.

Post-traumatic surgery accounts for about a quarter of splenectomies, but these procedures are decreasing in favour of alternative treatments (31). Another quarter of splenectomies are performed due to hematological disease, such as idiopathic thrombocytopenic purpura, sickle cell disease and hereditary spherocytosis. The remaining half of these surgeries are associated with solid tumors, or the result of accidental injury to the spleen during laparotomy (31).

Hyposplenia or splenic atrophy can be congenital, or associated with a wide range of disorders, including coeliac disease, hepatic cirrhosis, haematological disease, and autoimmune disease (22).

Pneumococcal vaccination

At the present, two principally different pneumococcal vaccines are in use, the 23-valent polysaccharide vaccine (PPV23, Pneumovax[®], MSD), and the 13-valent protein conjugate vaccine (PCV13, Prevenar 13[®], Pfizer). In PCV13, the polysaccharides are covalently linked to carrier protein CRM197, i.e. recombinant diphtheria toxoid. Twelve serotypes are included in both vaccines, with additional 11 serotypes in PPV23, and serotype 6A is only included in PCV13 (Table 1). Their principally different effects on the immune system, advantages and disadvantages will be addressed in this section.

Table 1.
Serotypes included in PPV23 and PCV13.

	1	2	3	4	5	6A	6B	7F	8	9N	9V	10A	11A	12F	14	15B	17F	18C	19A	19F	20	22F	23F	33F	
PPV23	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PCV13	+	-	+	+	+	+	+	+	-	-	+	-	-	-	+	-	-	+	+	+	-	-	+	-	-

Vaccine immunology

Antigen-specific antibodies generally mediate the early protective efficacy of vaccines, but long-term immunity can depend on both persistence of antibodies and/or memory cells (33). B cells can differentiate into antibody-secreting plasma cells but the production of high-affinity antibody and long-lasting memory B cells generally requires help from T cells. Cell surface markers, called cluster of differentiation (CD), are used to identify immune cells. Important subgroups of T lymphocytes are the CD4⁺ T helper cells, and CD8⁺ cytotoxic T cells. The CD4⁺ T helper (Th) cells are further divided into different phenotypes with specific roles within the immune system (table 2). The T helper 1 (Th1) cells express the chemokine receptor CXCR3 (34), produce cytokines such as interleukin(IL)-2, interferon- γ (IFN- γ) and tumor necrosis factor (TNF), and support CD8⁺ T cells and macrophages in immune responses against intracellular pathogens, e.g. virus and mycobacteria. The T helper 2 (Th2) cells secrete signature cytokines IL-4 and IL-5, IL-10 and IL-13, providing support to B cells in the defence against parasites (33). The T helper 17 (Th17) cell and its signature cytokine interleukin-17 (IL-17) was

first described in 1995 (35). The Th17 cells express the chemokine receptor CCR6 (36), and their main function is in the defence against extracellular bacteria, e.g. pneumococci, and fungi on mucosal surfaces (33). Another subset, the Th9 cells secrete IL-9, and are involved in the response to extracellular pathogens. Regulatory T cells (Tregs) control effector Th cells and mediate immune tolerance (33). The follicular T helper (Tfh) cells express CXCR5 (37), and specialize in providing help to B cells in germinal centre reactions in secondary lymphoid organs, resulting in the formation of plasma cells and memory B cells.

Table 2.

Relevant CD4⁺ T helper cell subsets, markers, cytokines and functions.

Subset:	Surface markers:	Signature cytokines:	Function in immune system:
Th1	CD183 ⁺ (CXCR3 ⁺)	IL-2, IFN- γ , TNF	Response to intracellular microbes
Th2	CD183 ⁻ , CD196 ⁻	IL-4, 5, 10, 13	Response to parasites
Th9	CD183 ⁻ , CD196 ⁺ (CCR6 ⁺)	IL-9	Response to extracellular pathogens
Th17	CD183 ⁻ , CD196 ⁺ (CCR6 ⁺)	IL-17, 21, 22	Response to extracellular bacteria and fungi
T regulatory cell (Treg)	CD25 ⁺	IL-10	Regulatory function, maintaining tolerance/preventing autoimmunity
T follicular helper (Tfh)	CXCR5 ⁺ , PD-1 ⁺ , ICOS ⁺	IL-21	Specialized B cell helper in germinal center reaction

T cell independent response to polysaccharide vaccine

The polysaccharide (PS) antigens of PPV23 activate B cells in the absence of T cell help, thus the immune response is termed T cell independent (TI). After immunization, PS antigens in the circulation reach the marginal zone of the spleen or lymph nodes, where cross-linking of surface Ig-receptors activates MZ IgM⁺CD27⁺ memory B cells in extrafollicular foci (22, 38). Within a week the MZ B cells differentiate to antibody-secreting plasma cells producing intermediate-affinity IgG antibodies, but absent or small numbers of memory cells (33). Repeated pneumococcal PS immunizations cause hyporesponsiveness, and gradual depletion of the memory B cell pool (39).

T cell dependent response to protein conjugate vaccine

Protein conjugate vaccines, as well as protein, toxoid, inactivated, or live attenuated viral vaccines, elicit T cell dependent (TD) immune responses resulting in high-affinity antibodies and immune memory (33).

The extrafollicular reaction

After injection of PCV, the repetitive structure of PS antigen cross-links the surface Ig receptors on naïve B cells, resulting in their activation. Activated B cells express

chemokine receptor CCR7, which causes homing of the cells towards the T cell zone of secondary lymphoid organs (33). The extrafollicular reaction with help from T cells causes B cells to differentiate into antibody secreting plasma cells that rapidly produce low-affinity unmutated germ-line IgM and small amounts of IgG within days of immunization. These plasma cells have a short life ended by in-situ apoptosis (40).

T follicular cells and the germinal centre reaction

In the first phase (days 0-3) after vaccine injection, the protein-PS conjugate is internalized by tissue dendritic cells (DC), and the protein part of antigen is processed for display on the major histocompatibility complex (MHC) class II surface receptor (41). Activated DCs migrate to the lymph nodes and express costimulatory surface molecule B7 for T cell activation. Activation of naïve T cells requires at least two signals, T cell receptor (TCR) – MHC class II-antigen interaction, and co-stimulatory signal from CD28-B7 interaction. T cell activation initiates the T follicular helper cell (Tfh) differentiation program, starting with the pre-Tfh cell, which express high levels of surface molecules PD-1 and inducible co-stimulator (ICOS) (41). Further, pre-Tfh cells gain expression of CXCR5 and loose CCR7, resulting in migration towards the T-B-cell junction.

The second phase (days 4-5), is the interaction between the pre-Tfh cell with antigen-presenting B cells which finalizes the CD4⁺CXCR5⁺ICOS⁺PD-1⁺ Tfh cell phenotype, and result in the migration of both Tfh and B cells toward the follicle (41).

In the third phase (days 6-10) B-cells proliferate in the primary follicle to form the germinal center (GC) (41). In the GC, B cells circulate between a dark zone (DZ) and a light zone (LZ) (42). In the DZ, B cells undergo somatic hypermutation (SHM) in the variable regions of light and heavy chain genes. The next step is affinity selection in the LZ, where B cells with higher affinity B cell receptors (BCRs) are able to retrieve peptide antigen from follicular DCs. The antigen is internalized, and B cells present it on MHC class II to Tfh cells. Successful presentation results in B cell survival, proliferation, and recycling in a new round of SHM in the DZ. When affinity maturation is complete, B cells leave GC and differentiate into high-affinity plasma cells and switched memory B cells (42).

Principal differences in the immune response to pneumococcal conjugate compared to polysaccharide vaccines

Pneumococcal conjugate vaccines elicit strong antibody responses in infants, in contrast to PS vaccines which are poorly immunogenic during the first 2 years of life, possibly due to immaturity of the splenic marginal zone (33). Theoretically, PCV has the advantage of the TD immune response with the formation of high affinity antibodies and memory B cells. Further, conjugate vaccines can induce neutralising antibody responses at mucosal surfaces, thus preventing bacterial colonisation (33). In contrast to PPV23, PCV seems to be independent of splenic marginal zone tissue, and therefore hypothesized to be more immunogenic in asplenic populations (22). Pneumococcal conjugate vaccines might be more immunogenic in healthy adults, but the evidence is inconclusive (43).

Efficacy

Pneumococcal polysaccharide vaccine efficacy for the prevention of IPD is around 50-80 %, in immunocompetent adult and elderly populations (44). The evidence regarding PPV efficacy against non-bacteremic pneumococcal pneumonia is inconclusive (45). A double-blind placebo-controlled randomized clinical trial (RCT) did not demonstrate efficacy of PPV23 in the prevention of all-cause or pneumococcal pneumonia in RA patients (46). In contrast, the 10-year relative risk of pneumonia was 9.7 in non-vaccinated compared to PPV23 vaccinated RA patients treated with MTX, in a retrospective study (47).

In a large trial (CAPITA) in the Netherlands, about 85,000 adults aged 65 years or older were randomized to receive either PCV13 or placebo. The CAPITA trial demonstrated 45.0% efficacy of PCV13 against vaccine-type non-bacteremic pneumococcal pneumonia, and 75.0% efficacy against vaccine-type IPD, but there was no effect on mortality (48). The CAPITA study has been criticized because the protective effect of PCV13 was compared to placebo, instead of PPV23 (49). In a meta-analysis by Moberley et al., the efficacy of PPV23 against IPD was 80%, which is similar to the efficacy of PCV13 reported in the CAPITA study (50).

A study conducted in Malawi, randomized 496 HIV infected persons to immunization with either two doses of PCV7 or placebo four weeks apart, and demonstrated 74 % efficacy against IPD (51). In a placebo controlled RCT in Uganda, PPV23 was ineffective for prevention of IPD in HIV infected adults (52). To the author's knowledge, pneumococcal vaccine efficacy studies in other immunocompromised populations are largely lacking.

Epidemiology of IPD in the era of PCV

In the United States, one year after the introduction of PCV7 in the childhood immunization program in 2000, IPD incidence decreased by 69 % in children < 2 years (53). In 2007, overall IPD incidence had dropped by 76 % in children < 5 years, and 45 % in all age groups, compared to the prevaccine era (54). Similar indirect protective effects in non-vaccinated populations due to herd immunity have been observed with PCV13 (45).

In England and Wales, the post-PCV13 overall IPD incidence in 2016/17 was 37 % lower in all age groups, compared to the pre-PCV7 period (55). Although PCV7-type IPD incidence had decreased by 97 %, and additional PCV13-type by 64 %, rapid increases in IPD caused by non-PCV13 serotypes have been observed in the adult population (55). Serotype replacement reduces the effect of PCV13 vaccination in the immunocompromised population. In Sweden, PCV13-type IPD only accounted for about 30 % of all IPD cases in 2019 (56).

Combination of PCV13 and PPV23

Since 2012, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for adults with immunocompromising conditions is to receive immunization with a dose of PCV13, followed after at least 8 weeks by a dose of PPV23, because of the wider serotype coverage (57). The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG) also recommends that at-risk adults receive this vaccine schedule (58), which is referred to as the prime-boost pneumococcal vaccination strategy (59).

In a RCT by Lesprit et al., 212 HIV patients either received PCV7 followed by PPV23 after 4 weeks or PPV23 alone at week 4 (59). No differences in antibody response were found 4 weeks after PCV or PPV, but patients who received the prime-boost vaccination strategy were more likely to achieve 2-fold increase in serotype-specific IgG and ≥ 1 $\mu\text{g/mL}$ in IgG level at week 8, and the differences remained significant at week 24. Similar results have been reported for PCV13 followed by PPV23 in HIV patients (60). In contrast, in liver transplant or renal transplant recipients the prime-boost strategy did not improve immunogenicity, compared with single dose PPV23 (61, 62). In a trial by Nguyen et al., RA patients treated with biologics were randomized to single dose PCV13 followed by PPV23 after 16 or 24 weeks or double dose PCV13 followed by PPV23 after 16 weeks, without differences in early antibody response (63).

Measuring antibody response to pneumococcal vaccines

Antibody responses following pneumococcal vaccination are evaluated through IgG quantification, most commonly using enzyme-linked immunosorbent assay (ELISA), and functionality of antibodies, i.e. opsonophagocytic activity (OPA).

Enzyme-linked immunosorbent assay

The first step in the pneumococcal enzyme-linked immunosorbent assay (ELISA) is to coat microtiter plates with specific pneumococcal capsular PS. In a preabsorption step, pneumococcal C PS is added to patient serum to reduce cross-reacting antibodies, and a WHO validated protocol also uses preabsorption with 22F PS (64). Patient serum is then added to the ELISA plates, and specific IgG antibodies bind to their corresponding antigen. In the next step, goat anti-human IgG antibodies conjugated with alkaline phosphatase are added to the plates, followed by addition of the substrate, nitrophenyl phosphate. The enzyme causes the substrate to change color, and the measured optical density is proportional to the IgG concentration. The method is calibrated using a reference serum provided by the United States Food and Drug Administration (FDA) (65). Reference serum 89SF has been replaced by 007Sp in the standard WHO validated method (64).

Opsonophagocytic activity

The most important defence mechanism against pneumococci is opsonisation by anticapsular antibodies, followed by phagocytosis and killing of the bacteria. Therefore functional assays measuring OPA are considered more biologically relevant, compared to IgG quantification methods. The killing-type OPA measures the titer of sera that reduce live bacteria by more than half (65), and such a method described by Romero-Steiner has become the standard in pneumococcal vaccine evaluations (66). Opsonophagocytosis can also be measured with flow cytometric assays, using fluorescent-labeled bacteria and phagocytes (67).

Putative protective thresholds

Optimal serotype-specific correlates of protection against IPS in adults are unknown, and licensure of new pneumococcal vaccines rely on demonstration of non-inferiority for each of the common serotypes compared to a licensed PCV (65). Higher levels of antibody might be required to confer protection against mucosal colonization or acute otitis media, compared to IPS. The World Health Organization (WHO) has recommended a protective threshold ≥ 0.35 $\mu\text{g/mL}$ of serotype-specific

IgG following conjugate immunization in infants (68). However, immunogenicity varies between different serotypes, e.g. for serotype 3 it is high, while serotypes 6B and 23F have lower immunogenicity (69). A study in England and Wales used an indirect cohort method to determine serological correlates of protection in infants, and suggested the aggregate threshold $\geq 0.8 \mu\text{g/mL}$ for all serotypes in PCV13, except serotype 3 for which the correlate was higher and protection was non-significant (70). In the same study protective thresholds for serotypes 6B and 23F were lower (0.16 and 0.2 $\mu\text{g/mL}$). Serotype-specific IgG $\geq 1.0 \mu\text{g/mL}$ is commonly used as a threshold of putative protection in adults. Chronic arthritis patients with antibody responses $\geq 1.0 \mu\text{g/mL}$ after vaccination with pneumococcal conjugate vaccine were less likely to suffer from serious infections (71). The American Academy of Allergy, Asthma & Immunology (AAAAI) has recommended a putative protective IgG level for each serotype $\geq 1.3 \mu\text{g/mL}$ (69). It is not uncommon for healthy nonimmunized adults to have protective antibody levels to one or a more serotypes after previous clinical or subclinical infections (69). The higher the preimmunization serotype-specific IgG level, the less likely the serotype will increase significant after vaccination (72), but most patients with preimmunization IgG $\geq 1.3 \mu\text{g/mL}$ will be able to mount a 2-fold increase after vaccination (73).

Autoimmune inflammatory rheumatic disease

Rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation primarily engaging the joints of the hands and feet in a symmetric pattern, and if untreated it will eventually lead to destruction of the joints.

Epidemiology

The prevalence of RA is 0.5-1.0 % in western populations (74, 75). Similarly, in a study from the Democratic Republic of the Congo, the reported prevalence was 0.6 % (76). Native American populations have the highest prevalence of RA, 6-8 % (77).

Classification criteria

The American College of Rheumatology (ACR) classification criteria for RA from 1987 (78) have been used as inclusion criteria in many studies. The revised classification criteria by ACR and European League Against Rheumatism (EULAR) from 2010 are shown in table 3 (79).

Disease activity, DAS28

The 28-joint disease activity score (DAS28) has been widely used to evaluate disease activity of RA patients in clinical trials since it was introduced in 1995 (80). The following formula is used for calculation of DAS28:

$$DAS28 = 0.56 \times \sqrt{TEN28} + 0.28 \times \sqrt{SW28} + 0.70 \times \ln(ESR) + 0.014 \times SA$$

TEN28 = number of tender joints (0-28), SW28 = number of swollen joints (0-28), ESR = erythrocyte sedimentation rate, SA = self-assessment of disease activity during the preceding 7 days (0-100).

Disease activity can be categorized by DAS28 as follows: <2.6 remission; 2.6-3.2 low; >3.2-5.1 moderate; >5.1 high.

Table 3.
The ACR/EULAR classification criteria for RA.

	Score
Target population (Who should be tested?): Patients who	
1) have at least 1 joint with definite clinical synovitis (swelling)	
2) with the synovitis not better explained by another disease	
Classification criteria for RA (score-based algorithm: add score of categories A–D; a score of ≥6/10 is needed for classification of a patient as having definite RA) [‡]	
A. Joint involvement	
1 large joint*	0
2–10 large joints	1
1–3 small joints** (with or without involvement of large joints)	2
4–10 small joints (with or without involvement of large joints)	3
>10 joints (at least 1 small joint)	5
B. Serology*** (at least 1 test result is needed for classification)	
Negative RF <i>and</i> negative ACPA	0
Low-positive RF <i>or</i> low-positive ACPA	2
High-positive RF <i>or</i> high-positive ACPA	3
C. Acute-phase reactants (at least 1 test result is needed for classification)	
Normal CRP <i>and</i> normal ESR	0
Abnormal CRP <i>or</i> abnormal ESR	1
D. Duration of symptoms	
<6 weeks	0
≥6 weeks	1

* "Large joints" refers to shoulders, elbows, hips, knees, and ankles.
 ** "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists.
 *** Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; low-positive refers to IU values that are higher than the ULN but ≤3 times the ULN for the laboratory and assay; high-positive refers to IU values that are >3 times the ULN for the laboratory and assay. Where rheumatoid factor (RF) information is only available as positive or negative, a positive result should be scored as low-positive for RF. ACPA = anti-citrullinated protein antibody.
 CRP = C-reactive protein; ESR = erythrocyte sedimentation rate.

Immunopathology of RA

The CD4+ T helper cells arguably have central roles in the immunopathology of RA. First, memory CD4+ T cells are increased in the inflamed synovial tissue of RA patients (81). Second, therapy inhibiting the activation of T cells, i.e. co-

stimulation blockade at the CD80/86–CD28 interaction is an efficient therapy in RA (82). Third, RA is associated with several risk alleles of the human leukocyte antigen (HLA)-DRB1 gene within the MHC class II region (83). The HLA-DRB1 risk alleles encode a specific amino acid sequence, the shared epitope (84). About 2/3 of RA patients have antibodies against cyclic-citrullinated peptides (anti-CCP), associated with HLA-DRB1 risk alleles (85).

B cells

Although RA is often considered a T cell-driven disease, several aspects of the disease are mediated by B cells. Rheumatoid factor (RF), an autoantibody directed against the Fc part of the IgG molecule, is a disease marker with sensitivity and specificity in RA around 70% and 85% respectively (86). Anti-CCP antibodies are more specific, 95% (86), and high titers are associated with poor prognosis (87). Perhaps the most important argument for an important role of B cells in the pathogenesis of RA is the efficacy of rituximab anti-CD20 B cell depletion therapy in RA refractory to TNF-blockade (88). This effect is not directly related to autoantibody production, as plasma cells lack expression of CD20.

Accumulation of pre-switch memory B cells (CD19⁺CD27⁺IgD⁺) in synovial tissue might explain that frequencies of these cells are decreased in peripheral blood of RA patients (89). In contrast, switched memory B cells (CD19⁺CD27⁺IgD⁻) are increased in peripheral blood and correlate with disease duration in RA (89).

T helper 1 cells

RA has been described as a Th1-driven disease, with an imbalance of Th1/Th2 cytokines (90). Th1 cells are present in the synovial fluid and tissue in RA, and these cells activate macrophages to produce the pro-inflammatory cytokine tumor necrosis factor (TNF) (36). TNF-blockade is an efficient therapy in RA (91).

T helper 17 cells

The Th17 cells produce the cytokine IL-17 which contributes to recruitment of neutrophils, in the defence against extracellular pathogens. In patients with RA, Th17 cells were found to be either increased or in normal numbers in the blood, compared to healthy subjects (36). Production of IL-17 can induce neutrophil inflammation in the synovial tissue and bone resorption in RA patients, but clinical studies have not shown efficacy of treatments targeting IL-17A or IL-17 receptor in RA (92, 93).

Follicular T helper cells

It has been shown that Tfh cells are able to exit GCs, and develop into memory Tfh cells (94), and blood CXCR5⁺ Th cells are thought to represent a circulating memory compartment of Tfh lymphocytes (cmTfh) (95). Further, cmTfh cells consist of

subsets cmTfh1 (CXCR3⁺CCR6⁻), cmTfh2 (CXCR3⁻CCR6⁻), and cmTfh17 (CXCR3⁻CCR6⁺) (95). Blood cmTfh2 and cmTfh17 can efficiently induce naïve B cells to produce class-switched immunoglobulins, but cmTfh1 cells lack this capacity (96). Several studies have shown increased percentages of cmTfh cells in RA patients compared to controls (97-100). In contrast, other studies found no difference in cmTfh, cmTfh1, cmTfh2 or cmTfh17 (101, 102), or lower percentages of cmTfh (103) in RA patients compared to healthy controls.

Regulatory T cells

Regulatory T cells and proinflammatory Th17 cells have opposite functions in the immune system. In mice, Tregs (CD4⁺CD25⁺) have the ability to prevent several autoimmune diseases (104). Tregs accumulate in synovial tissue and synovial fluid of RA patients, and proinflammatory cytokines such as TNF inhibit Treg suppressive function in vitro (36). In blood, CD45RA⁺ Tregs represent naïve cells, whereas CD45RO⁺ Tregs are previously activated cells (105). In RA patients responding to TNF-inhibitors, the treatment was shown to increase percentages of Tregs in blood (106).

Systemic vasculitis

The vasculitides are diseases characterized by inflammation and necrosis of different blood vessels, causing damage to the vessels, ischemia or aneurysm formation. Vasculitis is a heterogenous group of disorders with a diverse symptomatology, depending on which part of the blood vessel tree and organs are involved. Vasculitides can be divided into two main groups, i.e. infectious vasculitis, caused by direct invasion of microbes, e.g. syphilitic aortitis, rickettsial vasculitis or aspergillus arteritis, and noninfectious vasculitis (107). Noninfectious vasculitis is categorized by the 2012 revised nomenclature of the International Chapel Hill Consensus Conference (CHCC2012) (107). The primary categorization is based on the size of engaged blood vessels, i.e. large, medium or small vessels, although there are significant overlaps between these categories (Figure 1).




Figure 1. Vasculitides categorized on size of blood vessel involvement. Modified after Jennette et al. (107).
ANCA = Anti-neutrophil cytoplasmic antibody.

Diagnosis and classification

Before classification, three criteria must be fulfilled for the clinical diagnosis of primary systemic vasculitis, as described by Watts et al (108). The first criteria is symptoms or signs characteristic or compatible with ANCA-associated small vessel vasculitis (AAV) or polyarteritis nodosa (PAN) (e.g. upper or lower airway symptoms in granulomatosis with polyangiitis [GPA], or hematuria with red cell casts in renal vasculitis). Second, there should be histological proof of vasculitis and/or granuloma, positive serology for ANCA, specific investigations strongly suggestive of vasculitis (e.g. magnetic resonance angiography in PAN), or eosinophilia ($>10\%$ or $>1.5 \times 10^9/l$). The third criteria is exclusion of malignancy, infection (hepatitis B and C, HIV, tuberculosis and subacute bacterial endocarditis), drugs (e.g. cocaine), secondary vasculitis (RA, SLE, Sjögren's syndrome), other vasculitides (e.g. Behcet's, Takayasu's arteritis, giant cell arteritis), vasculitis mimics (e.g. cholesterol embolism), sarcoidosis and other granulomatous diseases. In analogy, diagnoses of large vessel vasculitides, i.e. Takayasu's arteritis and giant cell arteritis, are made on the basis of typical symptoms, typical histological or angiographic findings, elevated ESR and in the absence of findings suggestive of

infection, malignancy or other rheumatic disease. After clinical diagnosis, patients can be classified using the respective ACR 1990 criteria for eosinophilic granulomatosis with polyangiitis (EGPA), GPA, giant cell arteritis or Takayasu's arteritis (109).

Primary Sjögren's syndrome

Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by dryness of the eyes and mouth, hypofunction of salivary and lacrimal glands, and possible systemic manifestations. In patients diagnosed with another systemic inflammatory disease, usually RA or SLE, symptoms of dry eyes and mouth are referred to as secondary Sjögren's syndrome. The ACR/EULAR 2016 criteria for pSS are shown in table 4 (110).

Table 4. American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome.

The classification of primary Sjögren's syndrome applies to any individual who meets the inclusion criteria,* does not have any of the conditions listed as exclusion criteria,† and has a score of ≥ 4 when the weights from the 5 criteria items below are summed.

Item	Weight/score
Labial salivary gland with focal lymphocytic sialadenitis and focus score of ≥ 1 foci/4 mm ²	3
Anti-SSA/Ro positive	3
Ocular Staining Score ≥ 5 (or van Bijsterveld score ≥ 4) in at least 1 eye	1
Schirmer's test ≤ 5 mm/5 minutes in at least 1 eye	1
Unstimulated whole saliva flow rate ≤ 0.1 ml/minute	1

* These inclusion criteria are applicable to any patient with at least 1 symptom of ocular or oral dryness, for the definition see Shiboski et al. (106).

† Exclusion criteria include prior diagnosis of any of the following conditions, which would exclude diagnosis of SS and participation in SS studies or therapeutic trials because of overlapping clinical features or interference with criteria tests: 1) history of head and neck radiation treatment, 2) active hepatitis C infection (with confirmation by polymerase chain reaction), 3) AIDS, 4) sarcoidosis, 5) amyloidosis, 6) graft-versus-host disease, 7) IgG4-related disease.

Antirheumatic treatment

Corticosteroids

The corticosteroids have variable degrees of glucocorticoid and mineralocorticoid effects. The glucocorticoids have strong anti-inflammatory and immunosuppressive effects, mediated through both genomic and nongenomic mechanisms (111). Glucocorticoids bind to cytosolic glucocorticoid receptors, which act as ligand-

inducible transcriptional factors to activate anti-inflammatory and repress pro-inflammatory genes, such as nuclear factor κ B. The following effects are reduced cytokine production (e.g. IL-1, IL-6 and TNF- α), decreased chemotaxis and adhesion of leukocytes, impaired phagocytosis and lymphocyte anergy (112). Higher doses of glucocorticoids suppress antibody responses. Because of the quick onset of action and strong anti-inflammatory effects glucocorticoids are essential in the treatment of rheumatic diseases. However, their long-term use results in serious adverse effects, such as bacterial, viral and fungal infections, diabetes mellitus, hypertension, osteoporosis, psychosis, depression, skin atrophy and bruising. Severe organ involvement in AAV is often treated with intravenous pulses of methylprednisolone 1000 mg daily for three days, or oral prednisolone 1 mg/kg daily, which is tapered to 30-40 mg by one month, and 10-20 mg by three months (113).

Conventional disease-modifying antirheumatic drugs (DMARDs)

Methotrexate (MTX) has been the predominant treatment for rheumatoid arthritis patients since three decades (114). In the oncological setting, high doses (up to 1000 mg) of MTX antagonizes folate at the enzyme tetrahydrofolate reductase which blocks purine synthesis, resulting in cell cycle arrest at S phase and subsequent apoptosis of malignant cells (114). Low dose (15-25 mg/week) MTX has a half-life of 6 hours (115). Its positive antirheumatic effect consist of slow onset anti-inflammatory action, which is usually first noted after 4-8 weeks (116). The efficacy of MTX in RA is well-documented, a Cochrane Review concluded that the pooled numbers-needed-to-treat (NNT) to achieve 50 % improvement of disease parameters was 7 patients (117). The mechanisms behind the anti-inflammatory effects of low-dose MTX are still not fully understood (114). Methotrexate modulates cell-signalling pathways, which regulates the functions of most cells involved in inflammation (118). One of the most important mechanisms is MTXs ability to promote release of adenosine, which binds to cell surface receptors and exerts strong inhibitory effects on neutrophils, macrophages, T cells and other inflammatory cell types (119). When therapeutic monoclonal antibodies (Mabs) are used in combination with MTX, interaction between MTX and B-cell activation factor (BAFF) promotes adenosine release from regulatory B-cells which reduce immunization against Mabs (120).

Other antimetabolite DMARDs include the purine antagonist azathioprine (AZA), which in oral doses 50-200 mg daily have anti-inflammatory actions used mainly in treatment of SLE and systemic vasculitis (116). Mycophenolate mofetil (MMF) inhibits de novo synthesis of purines, leading to selective inhibition of lymphocyte proliferation, and is used in transplantation and treatment of AAV (121).

Cyclophosphamide (CYC) is an alkylating chemotherapeutic agent causing broad immunosuppression and B cell depletion, used in combination with glucocorticoids as induction therapy in severe cases of systemic vasculitis with internal organ involvement (113). It is either used in monthly or biweekly intravenous pulses or in daily oral doses. Adverse effects include bone marrow suppression, hemorrhagic cystitis, infertility and increased cancer risk.

Sulfasalazine (SSZ) is a slow acting anti-inflammatory drug, which is an alternative to MTX in treatment of RA patients. The anti-malaria drugs, chloroquine and hydroxychloroquine (HCQ), have moderate effects in combination with MTX or SSZ in RA patients, but are important treatments in SLE patients (116).

Biological DMARDs

Tumor necrosis factor (TNF) inhibitors, i.e. infliximab, etanercept, adalimumab, golimumab and certolizumab pegol, are inhibitors of the cytokine TNF-alpha. TNF-inhibitors are used in combination with MTX in RA patients not responding to MTX monotherapy.

Abatacept (ABT) is an efficacious treatment in RA patients not responding to TNF inhibitors (122). The mechanism of ABT is modulation of immune responses by binding to CD80/CD86 on antigen-presenting cells, thus preventing costimulatory binding of CD28 on naïve T cells and attenuating T-cell activation (Figure 2) (123). Treatment with ABT reduces levels of switched memory B cells (124). Abatacept is administered as a 500-1000 mg intravenous infusion, repeated after 2, 4 weeks, and followed by a dose every 4 weeks.

B-cell depletion therapy with anti-CD20 rituximab (RTX) causes almost total reduction of B-cells (>95%) in the circulation. The mechanisms of action of RTX are shown in Figure 3. It is used as step-up therapy in combination with MTX in RA patients who have failed to respond to TNF-inhibitors or abatacept. Rituximab is also used as an alternative to CYC for induction of remission in AAV patients, with comparable efficacy and adverse events (125, 126). In RA, the RTX regimen is 1000 mg twice over 2 weeks, and followed by treatment every 6 months. Common regimens in AAV are 375 mg/m² weekly for four weeks or 1000 mg twice in 2 weeks (113).

Expression of CD20 starts with pre-B cells in the bone marrow, but when naïve B cells differentiate into plasmacells, expression of CD20 is lost, which explains why long-lived plasmacells are resistant to RTX. If RTX treatment is discontinued, B-cells start replenishing after 6-9 months, but these are mostly naïve or transitional B-cells (127). One year after RTX treatment, 80% of CD27+ memory B cells were still depleted and their recovery can be delayed up to 5 years (128).




Figure 2. Mechanism of action of abatacept.

(A) Activation of naïve T cells requires at least two signals, T cell receptor (TCR) – MHC class II-antigen interaction, and co-stimulatory signal from CD28 – CD80/86 interaction. (B) Abatacept binds to CD80/CD86 on antigen-presenting cells (APC), thus preventing costimulatory binding of CD28 on naïve T cells and attenuating T-cell activation.




Figure 3. Mechanisms of action of rituximab.

(A) Complement-mediated cytotoxicity, (B) Direct lysis, or (C) FcγR/complement receptor-mediated opsonic phagocytosis or antibody-dependent cellular cytotoxicity. Modified after Taylor and Lindorfer (129). FcγR = Fcγ receptor. MAC = membrane attack complex.

Risk of infections in inflammatory rheumatic diseases

RA

Serious infections contribute to the increased overall mortality in patients with RA (130). The susceptibility to infections is likely due to a combination of immune pathology associated with underlying disease mechanisms in RA, comorbidities, and the use of immunocompromising drugs. Innate immune responses might be compromised by immune complex formation leading to impaired function and decreased numbers of neutrophils (131). Further, adaptive immune responses are impaired by limited T cell receptor repertoire (132), and reduced clonal expansion of naïve T cells in response to new antigen stimulation in RA patients (133).

In a retrospective cohort study by Doran et al., increased risk of infection requiring hospitalization (hazard ratio [HR]=1.8), was seen in RA patients after adjustment for confounders, e.g. glucocorticoid use, compared to age- and sex-matched non-RA controls (134). A second publication by the same authors reported age, extraarticular manifestations, leukopenia, and comorbidities such as diabetes mellitus, and corticosteroid use, to be strong predictors of infection in patients with RA (135). As previously described, the risk of IPD was more than doubled in RA patients compared to controls (28).

George et al. recently reported increased risk of hospitalized infections even with low dose glucocorticoids (≤ 5 mg/day) compared to no treatment in RA patients, and with higher doses a dose-dependent risk increase was observed (136). Corticosteroid treatment is a well-known risk factor for the opportunistic pneumocystis jiroveci pneumonia (137). Use of conventional (non-biologic) DMARDs without glucocorticoids has not been associated with increased risk of infectious complications in RA patients (138).

Treatment with TNF-inhibitors is well known to increase the risk of tuberculosis in RA patients (139-141), and is associated with reactivation of hepatitis B (142). In a meta-analysis, treatment with standard or high dose biological drugs with or without DMARDs was associated with increased risks of serious infections compared with traditional DMARDs (OR 1.3 and 1.9, respectively) (143). In a 2009 meta-analysis, RTX or ABT were not associated with significantly increased risks of serious infections compared with placebo, but this could have been due to the study being underpowered (144). Repeated courses of RTX are associated with hypogammaglobulinemia (145), and may also be associated with a higher rate of serious infections (146). A British biologics registry study, reported a higher risk of pneumocystis jiroveci pneumonia but lower risk of tuberculosis in RTX treated RA patients, compared with patients receiving TNF-inhibitors (147).

Systemic vasculitis

While immunosuppressive treatments are necessary in patients with systemic vasculitis, they come at the expense of life-threatening infectious complications (148). In AAV patients, infections are the most common causes of death during the first year after diagnosis, and contributes to increased morbidity and mortality for several years (149, 150). Lymphopenia, renal impairment and high-dose corticosteroids are known risk factors for severe infections in patients with AAV (151, 152).

The first year following diagnosis, patients with giant cell arteritis had doubled rates of severe infections, compared to age- and sex-matched controls, and treatment with prednisolone doses >10 mg/day one year after diagnosis was associated with increased infection related mortality (153).

Primary Sjögren's syndrome

Infections and cardiovascular disease are leading causes of mortality in pSS (154). Increased risk of pulmonary tuberculosis has been described in patients with pSS in Taiwan, and was associated with glucocorticoid use and higher age (155).

Pneumococcal vaccine response during antirheumatic treatment

Methotrexate

Our group and several others have reported impaired antibody response to pneumococcal and influenza vaccines in RA patients treated with MTX (156-160). However, the number of antigen specific plasmablasts in peripheral blood was not decreased (161).

Abatacept

Our group has previously demonstrated reduced antibody response to serotypes 6B and 23F after PCV7 in patients treated with ABT, and concomitant MTX in 76%, compared to healthy controls (162). Migita and colleagues reported similar reductions of antibody response following immunization with PPV23 in patients treated with ABT plus MTX, compared to MTX alone or RA with prednisolone monotherapy (163).

Rituximab

Previous studies have shown reduced antibody responses of either single dose PPV23 or PCV13 in RA patients treated with RTX (162, 164, 165).

Aims

The overall aims were to investigate:

- I.** The adherence to vaccination guidelines and the immunogenicity to PCV13 in splenectomized individuals.
- II.** The effect of standard of care therapy on antibody response following immunization using 13-valent pneumococcal conjugate vaccine (PCV13) in patients with systemic vasculitis compared to healthy controls.
- III.** If antibody response and functionality of antibodies following immunization with PCV13 is impaired in patients with RA and pSS without active anti-rheumatic treatment compared to RA patients treated with methotrexate (MTX), or to healthy controls.
- IV.** If the combined schedule of PCV13 followed by PPV23 improved antibody response compared with single dose PCV13 in patients with inflammatory rheumatic diseases (IRD) during various immunosuppressive therapies and in healthy controls.
- V.** The underlying mechanisms by which MTX exerts its effect on the antibody response using vaccination with PCV as a model for antigen challenge.

Patients and methods

Patient inclusion and pneumococcal immunization

Paper I

All patients who underwent splenectomy at the Central Hospital Kristianstad, Sweden, during the period January 2000 to October 2012 were identified using ICD-10 procedure codes for splenectomy (JMA00 or JMA10). Underlying diagnoses leading to splenectomy were noted. All patients received an invitation letter with a questionnaire regarding prior vaccinations, current medications or chronic illnesses affecting the immune system. Clinical records were scrutinized for additional information. Patients were enrolled in the study with an opt-out method, and after collection of informed consent. Patients were excluded if they had a history of allergic reaction at previous vaccinations, were pregnant, or had an ongoing infection. Participants completed all study visits at the Department of Infectious Diseases, Central Hospital Kristianstad, Sweden.

All participants who had neither received PCV13 previously nor PPV23 within the last year, and without contraindications, were immunized with one 0.5 mL dose of PCV13 (Prevenar 13®, Pfizer). Participants with a PPV23 vaccination within the last year also received dose of PCV13 if ≥ 2 pneumococcal serotype-specific IgG concentrations were below 0.35 $\mu\text{g/mL}$. PCV13 was administered as an intramuscular injection in the deltoid muscle.

Papers II and III

Adult patients with established systemic vasculitis (paper II), and RA or primary Sjögren's syndrome (pSS, paper III) who were regularly monitored at the Department of Rheumatology in Lund and Malmö at Skåne University Hospital were eligible for this study. In paper II, patients had to fulfil the American College of Rheumatology criteria for different systemic vasculitides (109). In paper III, patients had to fulfil the American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria for RA or pSS (79, 110). Ongoing treatment at the time of vaccination was noted as a basis for later patient stratification. Patients were excluded from the study if anti-rheumatic treatment had

been changed within 4 weeks before and 6 weeks after vaccination, if they had been previously vaccinated with PPV23 within 1 year, had a history of allergic reaction at previous vaccinations, were pregnant, or had an ongoing infection. Healthy control subjects were recruited from the staff and relatives at the department of Rheumatology in Lund.

Paper IV

Adult patients with inflammatory rheumatic disease, regularly monitored at the Departments of Rheumatology at Skåne University Hospital in Lund and Central Hospital in Kristianstad, were eligible for this study. Patients had to fulfil the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA or ACR criteria for systemic vasculitides (79, 109). Ongoing treatment at the time of vaccination was noted as a basis for later patient stratification. Patients were eligible for prime-boost pneumococcal vaccination if they had not previously received pneumococcal conjugate vaccine and they had not received PPV23 within the last 5 years. Patients previously immunized with one dose pneumococcal conjugate vaccine but no PPV23 within the VACCIMIL (Vaccination in Inflammatory Rheumatic Disease) study (166) were eligible for immunization with a PPV23 booster dose within the present study. Patients were excluded from the study if antirheumatic treatment had been changed within 4 weeks before vaccination, had a history of allergic reaction at previous vaccinations, were pregnant, or had an ongoing infection. Healthy control subjects were recruited from the staff and relatives at the Department of Rheumatology in Lund.

All participants fulfilling criteria for prime-boost pneumococcal vaccination were immunized with a single 0.5 mL dose of PCV13 (Prevenar 13[®], Pfizer), followed after 8 weeks by a single 0.5 mL dose of PPV23 (Pneumovax[®], MSD), administered as intramuscular injections in the deltoid muscle by a physician or nurse. Participants previously immunized with a single dose of PCV13 within the VACCIMIL study received a single 0.5 mL dose of PPV23 in the present study. In the RTX group ($n = 30$), a subgroup of 10 patients had previously received a single 0.5 mL dose of PCV7 (Prevenar[®], Pfizer), and they were immunized with a 0.5 mL dose of PPV23.

For all participants receiving prime-boost pneumococcal vaccination, serum samples were collected immediately before administration of PCV13 and PPV23 vaccines and 4–6 weeks after PPV23. For participants previously included in the VACCIMIL study, serum samples were drawn immediately before administration of PPV23 vaccine and 4–6 weeks after, and frozen serum samples taken immediately before and 4–6 weeks after prior PCV vaccination were re-analyzed

Paper V

Adult RA patients either planned to start methotrexate treatment (MTX-group), or without ongoing/planned DMARD treatment (ODMARD-group), at the Department of Rheumatology, Skåne University Hospital Lund were eligible for this study. Patients had to fulfil the American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria for RA (79, 109). At the time of inclusion, a rheumatologist performed a clinical examination and data were collected on disease and treatment characteristics and previous vaccinations using a structured protocol. Patients were excluded from the study if they had been treated with DMARD within 6 months, were treated with prednisolone >15 mg/day, if they had previously received pneumococcal vaccine, had a history of allergic reaction at previous vaccinations, were pregnant, or had an ongoing infection. Healthy controls were recruited from the staff and relatives at the department of Rheumatology in Lund.

All participants received a single 0.5 mL dose of PCV13 (Prevenar 13[®], Pfizer) administered as an intramuscular injection in the deltoid muscle. Patients in the ODMARD-group and healthy controls received immunization at time of inclusion. Patients in the MTX-group were immunized 6-12 weeks after start of methotrexate treatment and being on stable MTX dose for at least 4 weeks. At time of vaccination, a clinical examination was performed, and data was collected on disease activity.

Pneumococcal serology

Multiplex fluorescent microsphere immunoassay (MFMI) - Papers I, IV and V

Sera were frozen at -80° C and subsequently analyzed at Statens Serum Institut (SSI), Copenhagen, Denmark. Pneumococcal serotype-specific IgG concentrations were determined for the 12 capsular serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) common to both PCV13 and PPV23, using an in-house MFMI (Luminex) based on the procedure previously described by Lal et al. (167). This method permits simultaneous measurement of antibodies to all 12 serotypes in a single sample.

In short, pneumococcal PS purchased from SSI Diagnostica were conjugated to poly-l-lysine (PLL), and the PLL-modified PS were covalently bound to carboxyl microspheres (Luminex). Serum samples were first incubated with the PLL-PnPS-microspheres, and then with R-phycoerythrin conjugated anti-human IgG (Jackson ImmunoResearch Laboratories). The microspheres were analysed using a Bio-Plex

200 system (Bio-Rad). The assay was calibrated with international reference serum 89SF. Serotype-specific IgG concentrations were determined from a standard curve of median fluorescent intensity against expected IgG concentration for 89SF and converted to $\mu\text{g/ml}$.

In paper V, determination of pneumococcal serotype-specific IgG was performed using a different in-house MFMI at the Department of Clinical Immunology, Lund, Sweden. This method is also based on the method by Lal et al., but executed with some minor modifications. Pneumococcal polysaccharides (SSI Diagnostica A/S) were modified using 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM, Sigma Aldrich), and conjugated to magnetic carboxylated microspheres (COOH-DMTMM-method) (168). Cell wall PS (CWPS Multi, SSI Diagnostica A/S) was used for preadsorption. The assay was calibrated using pneumococcal reference serum 007Sp (NIBSC, Potters Bar, UK), according to the WHO standard protocol for pneumococcal ELISA (64).

Enzyme-linked immunosorbent assay (ELISA) – Papers II and III

Serum samples were collected immediately before and 4–6 weeks after vaccination. Serotype-specific IgG antibody concentrations for pneumococcal serotypes 6B and 23F, both included in PCV13, were quantified using enzyme-linked immunosorbent assay (ELISA) meeting World Health Organization (WHO) standard, described previously (64). The method was executed with minor modifications. In short, ELISA plates were coated with 1 μg pneumococcal capsular polysaccharides (PnPS) 6B or 23F. In order to diminish nonspecific binding, dilutions of human sera were adsorbed with pneumococcal cell wall PS, and then added to the ELISA plates. In contrast to the WHO protocol, 22F PnPS was not used for absorption. Goat anti-human IgG antibodies, conjugated with alkaline phosphatase, followed by addition of the substrate, nitrophenyl phosphate, were used for the detection of serotype-specific antibodies (anti-6B and anti-23F IgG). The optical density, proportional to the amount of anti-6B and anti-23F IgG present in the serum, was measured with an ELISA plate reader at 405 nm. The assay was calibrated with international reference serum 89SF, that was kindly provided by Dr. C. Frasch, Bethesda, MD, USA (169). This is also a modification to the latest WHO protocol which utilizes reference serum 007sp (64). The lower limit of detection was 0.01 mg/L.

Opsonophagocytic activity (OPA) assay – Papers II, III and IV

OPA assay was performed for pneumococcal serotype 23F (paper II and III), and serotypes 6B and 23F (paper IV). The method has been described by Martinez et al. (67) and was executed with some modifications.

Pneumococci of serotypes 6B and 23F obtained from Statens Serum Institut in Copenhagen, were cultured, killed by addition of glutaraldehyde and subsequently frozen in aliquots as described previously (170). Killed bacteria were thawed and incubated for 20–30 min in the dark with FITC (fluorescein isothiocyanate; F7250, Sigma-Aldrich, St. Louis, MO, USA) in sodium carbonate buffer, subsequently washed 3 times in VBS-CaMg (veronal-buffered saline with 0.15 mM Ca²⁺ and 0.5 mM Mg²⁺).

FITC-labeled bacteria (5×10^7 /mL), 20 μ L suspended in VBSCaMg were incubated with 10 μ L of heat-inactivated patient or control serum (prediluted 1/16 in VBS-CaMg) for 30 min at 37 °C. Subsequently 20 μ L of baby rabbit serum (CL3441, Cedarlane, USA) was added and incubation was continued for 30 min at 37 °C. Polymorphonuclear leukocytes from healthy donors, obtained as previously described (170) were preincubated with PE (Phycoerythrin)-labeled anti-CD66 (551480, BD Biosciences, Franklin Lakes, NJ, USA) and subsequently added to the opsonized bacteria at a final concentration of 800 cells/mL. After incubation for 30 min at 37 °C, cells were analysed with BD Accuri C6 flow cytometry (BD Biosciences). Results were expressed as percentage of cells (PE positive events) with significant uptake of bacteria (events positive for both PE and FITC). Inter-assay variation was compensated for by adjusting values to the mean value of a serum with high opsonizing ability, included in each analysis. A negative control consisting of bacteria preincubated only with BSA and no serum was also included in each analysis.

Phenotyping of lymphocytes with flow cytometry

Venous blood was obtained in heparin tubes, 4-6 ml (Becton Dickinson, BD, Vacutainer ref 369622). The tubes were stored dark at room temperature and all samples were analyzed within 24 h. The red blood cells were lysed by adding the blood to 45 ml 0.84% ammonium chloride for 10 min in room temperature. The lysed blood was then centrifuged for 10 min at 250 \times g. The cells were washed once with 50 ml PBS (without Mg²⁺ and Ca²⁺) and centrifuged for 10 min at 250 \times g. After centrifugation, the cell pellet was resuspended in 100 μ l FACS buffer (PBS + 0.5% BSA). The cells were divided in three tubes, 50 μ l cell suspension to each tube. 50 μ l of antibody mix was added to their respective FACS tube (for antibody mix, see supplemental table 1). The cells were incubated for 20 min, dark in room temperature. The cells were then washed by adding 3 ml PBS and centrifuged for 3 min at 250 \times g and resuspended in 250 μ l PBS. The analyses were performed on FACS Aria Fusion (BD Bioscience) using FACS Diva software. Cell populations were identified according to the gating strategies described by Maecker et al. (171).

Statistical methods

Differences between groups were analysed using the Chi-square test and the Mann-Whitney U test when appropriate.

Serotype-specific IgG concentrations as determined by ELISA or MFMI were log-transformed to calculate geometric mean concentrations (GMC) with 95% confidence intervals (CI). Pre- to postvaccine changes in specific IgG were compared using nonparametric (Wilcoxon's matched pairs signed rank test) or parametric paired statistics (paired T-test) as appropriate.

Antibody response ratio (ARR, i.e., the ratio of post- to prevaccination serotype-specific IgG concentration) was calculated, and positive antibody response was defined as $ARR \geq 2$. Because there is no international consensus definition of putative protective IgG concentration after pneumococcal vaccination, different thresholds were examined: $\geq 0.35 \mu\text{g/mL}$ (paper I), $\geq 1.0 \mu\text{g/mL}$ (papers I and II), $\geq 1.3 \mu\text{g/mL}$ (papers III and IV), and $\geq 5.0 \mu\text{g/mL}$ (paper I). Proportions of individuals with positive antibody responses and putative protective IgG were calculated with 95% confidence intervals (95% CI). Proportions of patients with putative protective levels pre- and postvaccination (matched pairs) were compared using McNemars test.

In paper IV, sums of serotypes with positive antibody responses and putative protective levels, respectively, were calculated for each study participant. Pre- to postvaccine differences within groups were tested using Wilcoxon matched-pairs signed-ranks test. We used multivariate linear regression to examine the possible influence of different exposure variables on outcome, i.e. number of serotypes with positive antibody response. The following variables were included in a multivariate regression model: gender, age (years), C-reactive protein (CRP, mg/L), ongoing rituximab (yes/no), abatacept (yes/no), conventional DMARD (cDMARD) (yes/no) and prednisolone dose (mg/day). In a stepwise selection procedure; (1) each variable was omitted in turn, *P*-value for each likelihood ratio test was recorded, and (2) the model was fitted with all variables except for the one with highest *P* value in step one. Step (1) and (2) were repeated until only variables with $P < 0.10$ were left to be included in the final model.

Possible monotonic associations between two variables were examined using Spearman's rank correlation test.

Results

Splenectomy patients (paper I)

In total, 78 patients underwent splenectomy at the Central Hospital Kristianstad between January 2000 and October 2012. The median age at the time of splenectomy was 61.5 years (range 11–88 years). Thirty-one individuals were deceased at the start of the study, and of these 5 patients (6.4%) had died within 14 days post-splenectomy. Twelve patients had died at the hospital, and the following causes of death were identified in records: pneumonia or sepsis of unknown etiology (n = 4), terminal cancer (n = 3), hemorrhage (n = 2), pneumonia and septic shock caused by non-encapsulated *Haemophilus influenzae* (n = 1), multitrauma (n = 1), and cardiac failure (n = 1). Nineteen patients had died in a hospice, nursing home or at home, and the final causes of death in this group is unknown to the authors but ten of these patients had been diagnosed with metastatic cancer.

Adherence to vaccination guidelines

Regarding vaccination against pneumococci, 64 individuals (81.0%) had received pneumococcal vaccine, with the following primary schedules: 1 dose PPV23 (n=59), and PCV13 followed by PPV23 after 8 weeks (n=5). The number of patients immunized against *Haemophilus influenzae* type B and meningococci (A+C polysaccharide or conjugated A, C, Y, and W-135 vaccine) were 41 (51.9%) and 18 (22.8%), respectively.

Immunogenicity of PCV13 in asplenic individuals with previous PPV23

Twenty-four splenectomized individuals received immunization with one dose PCV13. In this group, all had previously received PPV23, with the following doses (numbers of individuals; range of time since the last dose of PPV23): 1 dose (n=12; 0.8–13.0 years), 2 doses (n=10; 0.5–6.5 years) and 3 doses (n=1; 1.3 years). Mean years since vaccination was 4.6 (range 0.5–13.0 years). Nine individuals were classified as immunocompromised for the following reasons: hematological malignancies (n = 5), ongoing immunosuppressive treatment (n = 3, methotrexate or rituximab) and generalized solid organ malignancy (n = 1).

High levels of specific IgG were observed before immunization with PCV13, with GMC ≥ 0.35 $\mu\text{g/mL}$ for 10/12 serotypes (1, 4, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), and GMC ≥ 1.0 $\mu\text{g/mL}$ for 8/12 serotypes (1, 6B, 7F, 9V, 14, 19A, 19F, and 23F), in all study participants. In the immunocompromised subgroup, GMC ≥ 0.35 $\mu\text{g/mL}$ and ≥ 1.0 $\mu\text{g/mL}$, were observed respectively for 9/12 and 7/12 serotypes.

Serotype-specific IgG concentrations increased significantly pre- to post-PCV13 for pneumococcal serotypes 1, 3, 4, 5, 7F, 18C, 19A, 23F ($p \leq 0.001$), and 19F ($p = 0.01$, Figure 4). After PCV13, the following levels of IgG GMCs were observed: ≥ 0.35 $\mu\text{g/mL}$ (all serotypes), and ≥ 1.00 $\mu\text{g/mL}$ (all except serotype 3).




Figure 4. Geometric mean concentrations before and after PCV13 immunization in 24 patients who previously had received PPV23 .

Systemic vasculitis patients (paper II)

Forty-nine patients diagnosed with systemic vasculitides and 49 controls participated in the study. Diagnoses, disease characteristics, ongoing treatments and prior vaccinations are shown in Table 5. Patients receiving biologics were excluded from subgroup analyses because of small sample size. Remaining patients were stratified into two groups based on their treatment, as follows: Patients with MTX, AZA or CYC (n = 26); Patients with prednisolone monotherapy (n = 15). There was no age difference between MTX/AZA/CYC group and controls, but the prednisolone monotherapy group was older than controls (p = 0.003). In group 1, 81% of patients were diagnosed with GPA/EGPA, in contrast to group 2, in which 87% of patients were diagnosed with giant cell arteritis.

Table 5.

Demographic, diagnoses, disease characteristics, treatments and previous pneumococcal vaccination at the time of vaccination.

	All patients (n=49)	MTX/AZA/CYC (n=26)	Prednisolone (n=15)	Controls (n=49)
Age, median (range) years	65 (22-85)	61 (26-85)	70 (56-85)	57 (17-85)
Sex, % females	51	50	40	63
<u>Diagnoses, n (%):</u>				
Granulomatosis with polyangiitis (GPA)	21 (43)	16 (62)	1 (7)	-
Eosinophilic granulomatosis with polyangiitis (EGPA)	8 (16)	5 (19)	1 (7)	-
Giant cell vasculitis	13 (27)	0	13 (87)	-
Takayasu arteritis	4 (8)	2 (8)	0	-
Other vasculitis	3 (6)	2 (8)	0	-
<u>Disease characteristics:</u>				
Disease duration, mean (range) years	5.1 (0-42)	5.8 (0-42)	2.5 (0-18)	-
C-reactive protein, median (range) mg/L	2.3 (0-141)	2.2 (0-84)	5.4 (0-141)	0.8 (0-12)
Erythrocyte sedimentation rate, median (range) mm/h	10 (2-80)	10 (2-44)	14.5 (6-80)	-
<u>Ongoing treatments, n (%):</u>				
Azathioprine (AZA)	11 (22)	11 (42)	0	-
Cyclophosphamide (CYC)	6 (12)	6 (23)	0	-
Methotrexate (MTX)	9 (18)	9 (35)	0	-
Mycophenolate mofetil	2 (4)	0	0	-
Prednisolone	42 (86)	22 (85)	15 (100)	-
Rituximab	3 (6)	0	0	-
TNF inhibitor	2 (4)	0	0	-
No active treatment	2 (4)	0	0	-
Prednisolone dose, median (range) mg/day	7.5 (0-65)	5 (0-60)	12,5 (2.5-65)	-
<u>Previous vaccinations:</u>				
PPV23, n (%)	4 (8)	2 (8)	1 (7)	3 (6)

Safety

Localized pain or redness at the injection site, or headache was reported by 13 patients and 16 controls. A few patients experienced slightly increased body temperature and one patient reported general muscle pain and difficulties to move the upper arm where the vaccine was injected. All adverse reactions were considered mild and resolved within a few days.

Serotype-specific anti-pneumococcal antibody

Serotype-specific IgG increased for serotypes 6B and 23F, in both patient and control groups ($p < 0.001$, Figure 5). Postvaccination GMC (95% CI) for 6B and 23F were respectively in patients: 1.7 (0.9–2.9) $\mu\text{g/mL}$ and 1.8 (1.2–2.8) $\mu\text{g/mL}$, and in controls: 3.1 (1.9–5.0) $\mu\text{g/mL}$ and 3.3 (2.0–5.5) $\mu\text{g/mL}$. In patient subgroups 1 and 2, specific antibody increased for both serotypes.




Figure 5. Pneumococcal serotype 6B (A) and 23F (B) geometric mean concentrations before and after immunization with PCV13 in systemic vasculitis treatment groups and healthy controls.

* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Antibody response

No significant differences were found in the proportions of individuals with a positive antibody response (i.e. $ARR \geq 2$) to serotype 6B, 23F or both serotypes in all patients, or subgroups, compared to controls (Figure 6).




Figure 6. Responders (% with $ARR \geq 2$ for 6B and 23F) to immunization with PCV13.

Opsonophagocytic activity (OPA)

Phagocytosis of serotype 23F pneumococci as measured by OPA assay increased in both controls ($n = 36$) and patients ($n = 48$) after vaccination (both $p < 0.001$, Figure 7). Prevacination OPA was numerically lower in patients (0.0%) compared to controls (6.2%, ns). Postvaccination OPA was lower in patients (6.7%) compared with controls (31.9%, $p = 0.001$). Patients on DMARDs (group 1) had lower postvaccination OPA compared with controls ($p = 0.043$). Patients treated with prednisolone monotherapy (group 2) had lower both pre- and postvaccination OPA compared with controls ($p = 0.007$ and $p = 0.002$).

Correlations between ELISA IgG and OPA

After vaccination, there were significant correlations between serotype 23F IgG measured by ELISA and phagocytosis (%), in both patients (correlation coefficient = 0.33, $p = 0.02$) and controls (correlation coefficient = 0.54, $p = 0.001$).




Figure 7. Proportion of phagocytes (%) with uptake of pneumococcal serotype 23F.

Patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment (paper III)

A total of 60 patients with RA (50 without DMARD and 10 on MTX), 15 patients with pSS without DMARD and 49 controls were vaccinated. The demographic details, disease characteristics, pre- and postvaccination geometric mean antibody concentrations of the participants are shown in table 6.

Table 6. Demographic and patient characteristics in treatment groups and controls.

	RA 0DMARD (n=50)	RA MTX (n=10)	pSS 0DMARD (n=15)	Controls (n=49)
Age, median (range) years	66.9 (35-87)	67.4 (39-79)	62.3 (25-89)	57.2 (17-85)
Sex (% female)	78.0	70.0	87.0	63.3
Disease duration, mean (range) years	5.6 (0-36)	13.1 (2-40)	7.0 (0-23)	-
CRP, median (range) mg/L	7 (0-78)	3 (0-11)	1.7 (0.7-38)	-
ESR, median (range) mm/h	21 (4-71)	16 (5-42)	12 (7-66)	-
RF positive, %	78	80	43	-
Anti-CCP positive, %	69	70	8	-
DAS28, mean (range)	4.4 (1.8-6.2)	2.4 (1.7-3.1)	-	-
ANA positive, %	-	-	73	-
Anti-ENA positive, %	-	-	73	-
Anti-SSA (anti-Ro) positive, %	-	-	67	-
Anti-SSB (anti-La) positive, %	-	-	40	-
Prednisolone, %	58	0	13	0
Dose, median (range) mg/day	5 (0-15)	0	0 (0-10)	-
Previous PPV23, n (%):	1 (2)	0	0	3 (6)

DMARD = Disease modifying anti rheumatic drugs, RA = Rheumatoid arthritis, pSS = primary Sjögren's syndrome; CRP = C-reactive protein, ESR = Erythrocyte sedimentation rate; Anti-CCP = antibodies against cyclic-citrullinated peptides, ANA = Antinuclear antibodies, Anti-ENA = Antibodies against extractable nuclear antigens, Anti-SSA (anti-Ro) = Anti-Sjögren's-syndrome-related antigen A, Anti-SSB (anti-La) = Anti-Sjögren's-syndrome-related antigen B, RF = Rheumatoid factor.

Antibody response

Proportions of responders (i.e. $ARR \geq 2$) to serotypes 6B and 23F was lower in patients with RA on MTX treatment (both $p < 0.01$), but not in RA without DMARD or pSS without DMARD, compared to controls (Figure 8). Proportions of antibody responders to both serotypes did not differ between groups RA without DMARD (52 %), pSS without DMARD (40 %) and controls (55 %).




Figure 8. Proportions of responders to immunization with PCV13.

Putative protective levels

The proportions of participants with specific IgG $\geq 1.3 \mu\text{g/mL}$ for serotype 6B increased after vaccination in RA without DMARD ($p=0.001$) and controls ($p < 0.001$) but not in RA with MTX and pSS without DMARD. For 23F, increases were found in RA without DMARD ($p < 0.001$), pSS without DMARD ($p=0.05$) and controls ($p < 0.001$) but not in RA with MTX. The pre- to postvaccination percentage increase for serotype 6B and 23F respectively were 24% and 42% in RA without DMARD, 10% and 20% in RA with MTX, 14% and 26% in pSS without DMARD, and 28% and 40% in controls.

Opsonophagocytic activity (OPA)

After vaccination, phagocytosis measured with OPA assay (% uptake) increased in groups RA without DMARD ($p<0.001$), pSS without DMARD ($p=0.03$) and controls ($p<0.001$) but no increase was seen in patients with RA on MTX. Positive correlations between percentage change in OPA and pre- to postvaccination increase in ELISA were found for patients with RA without DMARD ($\rho=0.28$, $p=0.03$) and controls ($\rho=0.45$, $p=0.001$).

Predictors of positive antibody response

In a multivariate logistic regression model neither RA diagnosis (OR=1.2, 95% CI 0.5-2.6, $p=0.7$) nor age (OR=0.99, 0.96-1.0, $p=0.3$), but treatment with MTX was associated with a lower probability (OR=0.10, 0.01-0.87, $p=0.037$) of positive antibody response to both serotypes.

The higher the prevaccination serotype-specific IgG levels the less likely a significant rise in specific IgG will occur after immunization (72). Therefore, two separate models of the respective responses to 6B and 23F was made, using the same covariates but with added adjustment for prevaccine IgG level. Both models yielded similar results regarding the effect of MTX treatment on antibody response: 6B (OR=0.15, 0.03-0.89, $p=0.036$), and 23F (OR=0.09, 0.02-0.51, $p<0.006$), and for 6B prevaccination IgG was negatively associated with response (OR=0.56, 0.42-0.74, $p<0.001$).

Prime-boost vaccination strategy in patients receiving conventional DMARDs, abatacept and rituximab (paper IV)

Patients treated with rituximab (RTX, $n=30$), abatacept (ABT, $n=23$), or monotherapy with conventional DMARD (cDMARD, $n=27$, i.e. MTX/AZA/MMF), and 28 healthy controls participated in the study. All patients in the RTX group ($n=30$) had been started on treatment with RTX (at least 2 doses) before receiving PCV immunization (PCV13 $n=20$; PCV7 $n=10$), and had ongoing RTX at the time of PPV23 immunization. In the RTX group, 16 patients (53%) had concomitant treatment with MTX. In the ABT group ($n=23$), patients had ongoing treatment with ABT since at least 6 months, and 11 patients (48%) were also treated with MTX. Patients and controls were included in this study in accordance with Figure 9. Demographic data, diagnoses, disease characteristics, and medication details in the treatment groups and controls are summarized in Table 7.




Figure 9. Schematic of PCV and PPV23 immunizations and blood samples in treatment groups and controls.

Table 7.

Demographic, diagnoses, disease characteristics, and treatment at inclusion in study, in treatment groups and controls.

	Rituximab	Abatacept	cDMARD ¹	Controls
N	30	23	27	28
Female gender, %	53%	83%	74%	64%
Age, median (range) years	69 (31-88) ²	64 (42-78) ²	68 (25-87) ²	55 (18-84)
Rheumatoid arthritis, n (%)	27 (90%)	23 (100 %)	14 (52%)	0
RF-positive (% of RA patients)	100%	79%	90%	-
Anti-CCP-positive (% of RA patients)	92%	68%	80%	-
Granulomatosis with polyangiitis, n (%)	3 (10%)	0	7 (26%)	0
Eosinophilic granulomatosis with polyangiitis, n (%)	0	0	3 (11%)	0
Other systemic vasculitis, n (%)	0	0	3 (11%)	0
Disease duration, median (range) years	20 (2-57)	15 (4-45)	5 (2-46)	-
DAS28 in RA patients, median (range)	2.7 (0.5-6.5) ³	3.2 (1.5-5.5)	2.3 (1.6-4.3)	-
CRP, median mg/L	3.0	2.3	3.1	0.7
Total IgG, median (range) g/L	7.4 (4.0-13.9)	-	-	-
RTX duration, median (range) years	6.3 (0.7-10.9)	-	-	-
ABT duration, median (range) years	-	3.7 (0.7-10.2)	-	-
cDMARD duration, median (range) years	12.9 (3.3-22.4)	10.3 (4.2-20.3)	3.5 (1.4-15.3)	-
MTX, n (%)	16 (53%)	11 (48%)	19 (70%)	0
MTX mg/week, median	15	20	20	0
Azathioprine, n (%)	1 (3%)	0	5 (19%)	0
Azathioprine mg/day, median	150	0	100	0
Mycophenolate mofetil, n (%)	0	0	3 (11%)	0
Mycophenolate mofetil mg/day, median	0	0	1500	0
Prednisolone, n (%)	10 (33%)	10 (43%)	15 (56%)	0
Prednisolone mg/day, median (range)	5 (2.5-15)	5.6 (2.5-20)	5 (2.5-15)	0
Previous treatment with TNF α -inhibitor (%)	72.4	80.0	11.1 ⁴	0

1. Conventional disease-modifying antirheumatic drugs: methotrexate, azathioprine or mycophenolate mofetil.
2. All treatment groups were older than controls (all p<0.05).
3. DAS28 did not differ between treatment groups.
4. In the cDMARD group, compared to other treatment groups, a lower proportion of patients had previously received TNF α -inhibitor treatment.

Positive antibody responses

The numbers of serotypes with positive antibody responses ($ARR \geq 2$) in treatment groups and controls after PCV and PPV23 are shown in Figure 10. PCV13 + PPV23 compared to single-dose PCV13 resulted in an increased number of serotypes with positive responses in the ABT ($p = 0.016$), cDMARD ($p = 0.013$), and control groups ($p = 0.007$). Compared to controls, the numbers of serotypes with positive response after PCV + PPV23 were reduced in all patients groups ($p < 0.001$). Antibody responses after PCV13 and PCV13+PPV23 were lower in RTX group, compared to ABT and cDMARD groups ($p < 0.001$). There was no difference in antibody response in ABT compared to cDMARD group.





Figure 10. Antibody response to PCV and PPV23 in treatment groups and controls.

Median number of serotypes with positive antibody response after PCV13 and PCV13 + PPV23 in treatment groups and controls.

Putative protective levels

In the RTX group, the number of serotypes with specific IgG concentration $\geq 1.3 \mu\text{g}/\text{mL}$ increased slightly pre- to post-PCV (median 2 to 3, $p = 0.03$), but no further increase was seen post-PPV23 ($p = 0.98$, Figure 11). In the ABT group, there was a pre- to post-PCV13 increase from median 2 to 6 serotypes with protective

level ($p < 0.001$), but no changes were seen post-PPV23 ($p = 0.63$). The number of serotypes $\geq 1.3 \mu\text{g/mL}$ in the cDMARD group increased pre- to post-PCV13 (median 1 to 4, $p < 0.001$) and post-PPV23 (median 4 to 7, $p = 0.03$). Comparing treatment groups with controls, no significant differences in the number of serotypes with protective levels before vaccination were found. Post-PCV protective levels in the RTX, ABT, and cDMARD groups were reduced compared to controls ($p < 0.001$, $p = 0.02$, and $p = 0.002$). Post-PPV23 protective levels were reduced in all groups compared with controls (RTX, $p < 0.001$; ABT, $p < 0.001$; and cDMARD, $p < 0.001$). Post-PPV23 protective levels were lower in RTX group, compared to ABT and cDMARD groups ($p < 0.001$), but there was no difference between ABT and cDMARD groups.



* Immunizations in the RTX group (n=30): PCV13+PPV23 (n=20) and PC7+PPV23 (n=10)

Figure 11. Number of serotypes with specific IgG concentration $\geq 1.3 \mu\text{g/mL}$ after PCV13 and PCV13+PPV23 in treatment groups and controls.

Predictors of positive antibody response to prime-boost pneumococcal vaccination

A multivariate linear regression model was derived in a stepwise selection procedure, where gender, age, CRP, and prednisolone dose were omitted each in turn because of no association with the outcome (likelihood test, all $p \geq 0.10$), i.e., the number of serotypes with positive antibody response (Table 7). Rituximab was found to be an independent risk factor associated with a large reduction and abatacept and cDMARD with a moderate reduction in number of serotypes with positive antibody response (Table 8). Within the RTX group, the number of responding serotypes was not associated with rituximab treatment duration (data not shown). In a separate, multivariate regression model of positive antibody response in RA patients, DAS28 was not associated with the outcome ($p = 0.61$).

Table 8.

Predictors of number of serotypes (0-12) with positive antibody response, i.e. ≥ 2 -fold increase from prevaccination serotype-specific [IgG], after prime-boost vaccination.

Predictors:	Stepwise selection of exposure variables, p of likelihood ratio test				Multivariate linear regression model		
	1	2	3	4	Coefficient estimate	95 % CI	P
Intercept (control)					11.2	10.3, 12.1	<0.001
Rituximab (yes/no)	<0.001	<0.001	<0.001	<0.001	-8.6	-9.8, -7.4	<0.001
Abatacept (yes/no)	0.008	0.009	0.009	0.007	-1.9	-3.2, -0.6	0.005
cDMARD (yes/no)	<0.001	<0.001	<0.001	<0.001	-1.8	-2.8, -0.8	<0.001
Gender	0.11	0.13	0.13	0.10	Goodness of fit: Multiple $R^2 = 0.69$		
Age (years)	0.59	-	-	-			
CRP (mg/L)	0.38	0.39	0.36	-			
Prednisolone dose (mg/day)	0.56	0.63	-	-			

Opsonophagocytosis of pneumococcal serotypes 6B and 23F

In the RTX group, functionality of antibodies for pneumococcal serotypes 6B (Pn6B) and 23F (Pn23F), as measured by OPA assay, neither increased after PCV prime nor PPV23 boost immunization, and post-PPV23 OPA was reduced compared to controls (both serotypes $p < 0.001$). In the ABT group, OPA increased after immunization with PCV (Pn6B, $p = 0.002$ and Pn23F, $p = 0.008$) but did not increase further after PPV23, and post-PPV23 OPA for Pn23F was reduced compared to controls ($p = 0.020$). In the cDMARD group, OPA increased after PCV for Pn6B ($p = 0.017$) but did not increase further after PPV23. In this group, PCV13 + PPV23 resulted in increased OPA ($p = 0.003$) for Pn23F, and post-PPV23 OPA for Pn23F was similar to controls. There were no differences between post-PCV13 and post-PPV23 OPA in the control group.

Methotrexate reduced Th17 cells and impaired plasmablast and memory B cell responses after PCV immunization in RA patients (paper V)

Rheumatoid arthritis patients without ongoing or planned DMARD treatment (0DMARD group, n=12), RA patients planned to start MTX treatment (MTX group, n=11), and healthy controls (HC, n=13) were enrolled in the study. Disease activity was higher in the MTX group compared to the 0DMARD group ($p=0.01$). Demographics, laboratory and clinical data are summarized in Table 9.

Table 9. Demographic, clinical and laboratory characteristics and treatment.

	Healthy controls	RA 0DMARD	RA MTX
N	13	12	11
Age years, median (range)	40.0 (32.1-62.7)	56.6 (29.7-74.3)	63.1 (39.5-82.1) ¹
Gender, female	67 %	67 %	90 %
RF positive	-	75 %	100 %
ACPA positive	-	92 %	45 % ²
DAS28 at inclusion, median (range)	-	4.7 (2.9-7.0)	5.7 (4.6-7.5) ³
DAS28 at vaccination, median (range)	-	4.7 (2.9-7.0)	4.6 (2.2-6.0)
CRP at vaccination, mg/L	0.7 (0.6-5.3)	3.9 (0.6-9.1) ⁴	2.8 (0.6-14.0) ⁴
ESR at vaccination, mm	5 (2-19)	25.5 (5-66) ⁵	35 (4-64) ⁵
Disease duration years, median (range)	-	5.4 (0.1-54)	0.8 (0.1-29)
Prednisolone dose, median (range) mg/day	0 (0)	0 (0-5)	0 (0-15)
MTX dose at vaccination, median (range) mg/week	0 (0)	0 (0)	20 (15-25)

1. RA with MTX-start group were older than controls ($p=0.002$).
2. Percentage of ACPA positives were lower in RA with MTX-start compared to RA without DMARD ($p=0.02$).
3. DAS28 at inclusion was higher in group RA with MTX-start compared to RA without DMARD ($p=0.01$).
4. CRP at vaccination was higher in both RA groups compared to controls ($p<0.001$).
5. ESR at vaccination was higher in both RA groups compared to controls ($p<0.01$).

B cell and T cell subsets at baseline

Different stages of B cells (CD19⁺) were determined using a panel described by Maecker et al. (171). Total lymphocytes, B cell and T cell subsets are shown in Table 10. Switched memory B cells were higher in RA patients compared to HC ($p=0.034$ and $p=0.010$, Figure 12D), but did not correlate with disease activity (DAS28). Exhausted (IgD⁻CD27⁻) B cells, i.e. an antigen experienced non-functional phenotype (172), correlated with disease duration ($R=0.53$, $p=0.017$), and age of patients ($R=0.44$, $p=0.05$).

There were no differences in T cell subsets at baseline.

Table 2. Total lymphocytes and B and T cells with subsets at baseline.

	Healthy controls	RA ODMARD	RA MTX
Lymphocytes, $\times 10^9$ cells/L ¹	1.4 (1.0-2.4)	1.8 (0.9-2.5)	1.7 (0.7-2.5)
B cells , % of lymphocytes	5.7 (2.6-11.2)	4.8 (1.3-14.7)	10.2 (1.8-15.7)
Naïve, % of B cells	52.4 (40.9-69.2)	51.3 (18.9-74.8)	55.6 (24.7-82.5)
Transitional, % of naïve	7.9 (1.5-15.0)	6.5 (0.2-14.2)	3.3 (0.3-14.7)
Preswitch memory, % of B cells	7.0 (2.2-25.9)	10.0 (2.0-21.3)	6.0 (1.1-14.6)
Switched memory, % of B cells	14.8 (6.1-27.7)	27.0 (9.4-57.4) ²	23.4 (4.5-56.6)
Plasmablasts, % of switched	9.5 (2.4-30.9)	6.2 (1.9-14.3)	6.8 (1.6-11.3)
Exhausted, % of B cells	22.5 (4.9-36.1)	11.5 (4.0-24.9)	12.2 (6.1-30.4)
T cells , % of lymphocytes	72.7 (54.2-86.8)	75.4 (55.7-87.4)	72.0 (44.4-85.5)
HLA-DR ⁺ , % of T cells	1.9 (0.4-7.5)	1.8 (0.4-3.5)	1.7 (0.6-6.5)
CD38 ⁺ , % of T cells	9.3 (2.5-31.3)	14.9 (3.1-28.9)	8.5 (2.5-37.1)
NKT cells, % of T cells	7.5 (0.8-42.2)	12.2 (0.9-48.0)	9.4 (2.2-20.7)
CD4 ⁺ Th, % of T cells	66.4 (46.1-81.5)	51.6 (31.0-83.6)	66.6 (48.6-77.7)
Naïve Th, % of CD4 ⁺	49.0 (10.5-58.5)	38.9 (11.6-73.3)	42.5 (13.7-64.3)
TEMRA, % of CD4 ⁺	20.8 (8.4-62.0)	20.2 (11.9-67.3)	16.3 (4.2-43.0)
Central memory, % of CD4 ⁺	8.3 (0.1-22.1)	9.1 (3.4-21.8)	10.5 (4.5-47.8)
Effector memory, % of CD4 ⁺	18.4 (0.1-32.6)	20.2 (10.9-54.8)	19.7 (14.1-48.2)
Th1, % of CD4 ⁺	10.1 (5.0-23.5)	8.4 (4.0-15.6)	11.6 (2.2-19.5)
Th2, % of CD4 ⁺	18.7 (6.0-24.7)	16.8 (0.9-26.4)	15.2 (6.1-65.4)
Th17, % of CD4 ⁺	18.7 (8.6-28.7)	17.1 (8.7-33.7)	18.4 (7.4-56.0)
Treg, % of CD4 ⁺	2.8 (0.3-5.7)	1.2 (0.5-5.1)	2.0 (0.3-9.6)
Activated Treg, % of Treg cells	19.6 (7.4-32.3)	20.6 (8.4-43.0)	21.7 (1.9-52.2)
cmTfh, % of CD4 ⁺ CD45RO ⁺ T cells	21.3 (10.2-30.9)	22.7 (9.5-29.0)	14.3 (11.7-74.9)
cmTfh1, % of cmTfh cells	16.8 (9.8-24.5)	17.6 (11.3-23.6)	16.5 (9.7-29.4)
cmTfh2, % of cmTfh cells	17.5 (11.4-24.3)	18.8 (10.1-35.1)	22.9 (7.6-32.6)
cmTfh17, % of cmTfh cells	45.8 (35.8-60.5)	42.7 (27.0-57.5)	41.8 (26.4-58.5)
PD1 ⁺ ICOS ⁺ cmTfh, % of cmTfh cells	1.3 (0.3-5.1)	2.2 (0.1-7.5)	1.4 (0-3.8)
Tph, % of CD4 ⁺	0.7 (0.1-0.9)	0.8 (0.2-2.0)	0.9 (0.3-2.6)

Definitions of lymphocyte subsets and abbreviations are shown in Paper 5, Supplementary Table S2.

1. All results are presented as median (range).
2. Switched memory B cells were higher in RA ODMARD and all RA patients compared to HC ($p < 0.01$ and $p = 0.02$).

Switched memory B cells and plasmablasts after immunization

Switched memory B cells and plasmablasts increased after pneumococcal vaccination in HC and in the ODMARD group ($p \leq 0.03$), but no changes were seen in the MTX group (Figures 12A and 12B). After vaccination, plasmablasts were

lower in the MTX group compared to the 0DMARD group ($p=0.002$), and HC ($p<0.001$, Figure 12C).




Figure 12. Circulating switched memory B cells and plasmablasts in RA groups and controls. Concentrations of (A) switched memory B cells, and (B) plasmablasts in HC and RA 0DMARD groups: before and after PCV, and in RA MTX group: before start of MTX, before and after PCV. (C) Group comparison of plasmablast concentrations after PCV. (D) Group comparison of switched memory B cells at baseline and after PCV.

Effect of MTX treatment on Th17 cells in blood

Initiation of methotrexate treatment resulted in decreased Th17 cell frequencies (% of CD4⁺) and concentrations ($p=0.02$ and $p=0.03$, Figure 13). In HC, vaccination resulted in increased Th17 cell frequencies (% of CD4⁺, $p=0.03$) and concentrations ($p=0.01$, Figure 13), but no changes were seen in the RA groups.




Figure 13. Circulating T helper 17 cells in RA groups and controls.

T helper 17 cells in % of CD4⁺ (A), and concentrations (B), in HC and RA ODMARD groups: before and after PCV, and in MTX group: before start of MTX, before and after PCV.

Circulating T follicular helper cell subsets in relation to methotrexate and immunization

No effects of MTX on total or activated (ICOS⁺ PD-1⁺) cmTfh cells were found. Frequencies of total cmTfh cells (% of CD4⁺ cells) were unchanged after immunization in all groups (Figure 3A). Although non-significant, activated cmTfh cells (% of CD4⁺) increased after vaccination in 8 of 11 patients in the ODMARD group ($p=0.10$), 7 of 11 patients in the MTX group ($p=0.14$), and in 7 of 12 HC ($p=0.20$).

Pneumococcal antibody concentrations

Positive antibody responses (≥ 2 -fold increase in ≥ 6 of 11 serotypes) were seen in 90% of HC participants, 87.5% of the ODMARD group, and 56% of the MTX group. Mean fold change in pneumococcal IgG concentrations correlated with plasmablast concentrations in all participants ($R=0.52$, $p=0.011$), and all RA patients ($R=0.57$, $p=0.035$).

Discussion

Immunocompromised patients are at increased risk of serious infections, and some of these infections are vaccine-preventable. While immunizations with live vaccines are contraindicated in the immunocompromised host, non-live vaccines can often safely be administered but there is a risk of impaired immune responses and low vaccine efficacy. The population of immunocompromised patients is growing, and the patients with secondary immunodeficiency (SID) by far outnumber those with a genetic, primary immunodeficiency (112). A SID is defined by an extrinsic cause of the compromised immune system, such as malnutrition, HIV infection or treatment with glucocorticoids or immunomodulatory drugs. Splenectomized patients constitute a SID subpopulation with a specific defect in the immune defence against encapsulated bacteria. The use of immunosuppressive drugs in western populations is increasing, as more patients receive solid organ or bone marrow transplants, and as a consequence of higher proportions of patients with autoimmune inflammatory diseases who receive biological treatments. Among the B cell directed biological treatments, rituximab is used in the treatment of patients with RA or AAV, as well as in patients with haematological malignancies.

Post splenectomy patients

Adherence to guidelines for primary pneumococcal immunization in splenectomized patients was adequate. In contrast, there was poor adherence to recommendations regarding meningococcal immunization, as only one fourth of patients had documented immunization with meningococcal vaccine. Studies from France and Netherlands have shown similar results (173, 174).

High levels of pneumococcal serotype-specific IgG concentrations were seen in previously PPV23 immunized asplenic patients, and PCV13 was immunogenic as a booster dose with increases in specific IgG for 9 of 12 serotypes (1, 3, 4, 5, 7F, 18C, 19A, 23F, and 19F). To the authors knowledge this was the first study investigating immunogenicity of PCV13 in the asplenic population. In a study from the UK, Stanford et al. reported similar results regarding immunization with PCV7 in asplenic individuals (175).

The clinical implication of our results is that PCV13 can elicit adequate antibody responses in asplenic patients previously immunized with PPV23. Optimally PCV should be administered before PPV23, since several studies in adults have shown reduced immunogenicity of PCV 6-12 months after an initial PPV23 dose (176-179). The CDC/ACIP recommendation for asplenic patients is immunization with one dose PCV13 followed in ≥ 8 weeks by a PPV23 dose, and a PPV23 booster dose after 5 years (57). Patients with previous PPV23 are recommended immunization with a PCV13 dose ≥ 1 year after PPV23.

Due to small sample size, and heterogeneity of underlying reason for splenectomy, our results should be interpreted with some caution. Larger studies are needed to further investigate immunogenicity of PCV and optimal immunization schedules in asplenic patients.

Systemic vasculitis patients receiving standard of care therapy

We found that PCV was safe and immunogenic with increased IgG concentrations (6B and 23F), OPA (23F), and improvement of antibodies above threshold 1.0 $\mu\text{g/mL}$, after immunization of patients with systemic vasculitis. There were no differences in IgG after immunization or proportion of responders between all patients, subgroups and controls. However, treatment with cytotoxic drugs might impair antibody responses, as illustrated by the trend toward fewer patients in the AZA/MTX/CYC group (85% diagnosed with AAV) reaching IgG ≥ 1.0 $\mu\text{g/mL}$, compared to controls. We did not find an association between glucocorticoid dose and antibody response, but most patients were treated with low or moderate doses.

Although functionality of antibodies improved after immunization in all groups, post-PCV OPA was lower and correlation with ELISA was weaker in patients, compared to controls. In the glucocorticoid monotherapy group (87% GCA), both pre- and post-PCV OPA were lower compared to controls, probably due to higher age and a negative effect of glucocorticoids on phagocytosis.

Our results are in line with a study from the UK, which showed preserved immunogenicity to PCV7 in patients with AAV in remission (180). In a case series of AAV patients from France, decreased response to PCV \pm PPV23 was seen in 9 patients on induction therapy but not in 8 patients with maintenance therapy (181).

To the author's knowledge, this is the first study of both quantitative and functional antibody response after PCV immunization in patients with systemic vasculitis. Since this patient group is at high risk of severe infections, such as IPD, pneumococcal immunization should be a priority. Optimally immunizations should be performed before initiating any immunosuppressive treatment, but for patients

with rapidly progressive necrotizing vasculitis this is seldom possible. The clinical implication of this study is that immunization with PCV is safe and elicits adequate antibody responses in patients with systemic vasculitis and ongoing immunosuppressive therapy.

Patients with RA or primary Sjögren's syndrome patients without DMARD treatment

Antibody responses to PCV in RA or pSS patients without DMARD treatment were comparable to those of healthy controls. However, functionality of antibodies (OPA) after immunization was reduced in RA patients without DMARD, compared to controls. Similarly, correlation between change in OPA and ELISA was weak in RA without DMARD, and moderately strong in healthy controls. Higher age in RA patients and glucocorticoid treatment could probably explain reduced phagocytosis compared to healthy controls. In line with previous studies, the response in MTX treated patients was reduced (182).

The underlying autoimmune pathologies of RA and pSS are known to increase the risk of serious infections (28, 134, 155). Our findings, i.e. that pneumococcal conjugate vaccine was immunogenic in both RA and pSS without DMARD, support the use of this vaccination in newly diagnosed patients before starting immunosuppressive DMARD treatment.

Prime-boost pneumococcal vaccination in relation to rituximab, abatacept and cDMARD

In RTX treated patients, antibody response was not improved by prime-boost vaccination compared to single PCV dos, and the response was markedly impaired compared to healthy controls. This is in line with previous studies which have shown reduced antibody response to single dose PCV or PPV23 in RTX treated RA patients (162, 164, 165). Reductions in antibody responses could be expected since rituximab causes almost total depletion of B cells in the circulation. After RTX treatment is discontinued, it takes 6-9 months before B cells start replenishing, and most of these are naïve or transitional B cells (127), and most of the memory B cells (80%) are still depleted one year after RTX treatment (128). Our findings strongly support the recommendation to complete pneumococcal immunization before initiating RTX treatment.

We found reduced antibody response after the prime-boost vaccination strategy in ABT treated patients, for serotypes in common to PCV13 and PPV23, compared to controls. Although antibody response improved with PCV13+PPV23, compared to PCV13 alone, no change was seen in putative protective levels. A previous study from our group has shown reduced antibody response to PCV7 in ABT treated RA patients (76% with concomitant MTX), compared to healthy controls (162). In a study by Migita et al., antibody response to PPV23 was reduced in RA patients with ABT+MTX treatment compared to MTX or glucocorticoid monotherapy (163). Abatacept was also reported to reduce levels of switched memory B cells (124).

Our results support the recommendation to immunize against pneumococci before starting ABT treatment, but in patients with ongoing ABT and concomitant MTX, prime-boost vaccination could have a potential benefit over single dose PCV. Prime-boost vaccination strategy improved the number of serotypes with positive antibody response and IgG ≥ 1.0 $\mu\text{g/mL}$ compared to single-dose PCV, in IRD with conventional DMARD treatment. Several groups have reported that MTX treatment reduce antibody response to PCV or PPV23 in arthritis patients (182). Our results suggest that the prime-boost vaccination strategy is more likely to elicit a strong antibody response compared to single-dose PCV13 when initiation of conventional DMARD treatment can't be delayed.

Strengths and limitations with the pneumococcal serological assays

In papers II and III, pneumococcal IgG antibodies to serotypes 6B and 23F were quantified using an ELISA assay. Determining antibody levels to two of thirteen vaccine serotypes is an obvious limitation, and serotypes 6B and 23F are considered less immunogenic compared with other PCV13-types (69). However, since the aforementioned studies aimed to study the effects of immunosuppressive treatments and rheumatic disease on antibody response, rather than describing the response to different serotypes in detail, the authors believe this was a minor limitation.

Although the MFMI (Luminex) assay, used in papers IV and V, is a validated method, it has not been as extensively used and evaluated as the standard WHO ELISA (64). The advantages of MFMI over ELISA is that it allows for the rapid simultaneous quantification of antibodies to many serotypes.

Regardless of which serological assay is used, the quantification of antipneumococcal antibodies is only a surrogate marker for protection, in the absence of efficacy studies. Different protective thresholds have been described, e.g., 0.35 $\mu\text{g/mL}$ for children, 1.0 $\mu\text{g/mL}$ for adults, and 1.3 $\mu\text{g/mL}$ for immunocompromised adults (69). While antibodies in the range of 0.20 to

0.35 µg/mL can protect against bacteremia, ten times higher antibody levels may be required to prevent pneumonia, otitis media and nasopharyngeal carriage (70, 183).

In general, functionality of antibodies measured by an OPA assay offers a more biologically relevant picture, compared to IgG quantifications. We used an in house flow cytometry based OPA assay, and although it is a validated method (67), it differs from the killing type OPA method which has become a gold standard for pneumococcal vaccine evaluations (184),.

Methotrexate reduced circulating Th17 cells and impaired memory B cell and plasmablast responses after immunization

Immunization with PCV was associated with increases in the concentrations of circulating plasmablasts and switched memory B cells in HC and RA patients without DMARD treatment, but these changes were not seen in MTX treated patients. These subsets of B cells are considered antigen experienced after TD germinal centre reactions in secondary lymphoid organs (42). Although nonspecific B cells were measured in this study, the results are in line with previous findings of reduced antibody responses to PCV in MTX treated arthritis patients (158). Methotrexate is known to increase extracellular levels of adenosine, which has potent inhibitory effects on many inflammatory cell types (118). Interaction between MTX and BAFF, promoting adenosine release, has been proposed as the mechanism behind reduced immunization against therapeutic Mabs in patients receiving a combination of MTX and TNF-inhibitors (120).

Initiation of MTX treatment in RA patients lead to a reduction in Th17 cells in blood, which is similar to the findings of Szalay et al. (185), and consistent with an in-vitro study by Guggino et al. (186). Shen et al. previously demonstrated increased frequencies of IL-17 producing T cells in PBMCs from RA patients and strong correlation with disease activity (187). T helper 17 cells are defenders against extracellular bacteria, e.g. pneumococci, on mucosal surfaces (33), and these cells could be critical for vaccine induced memory immune responses (188).

The effects of MTX on Th17 cells, switched memory B cells, and plasmablasts could have implications for both vaccine-induced antibody and long-term immune memory responses.

Future perspectives

The limitations of vaccine type protection and serotype replacement in the population drives the development of new pneumococcal conjugate vaccines with wider spectra of serotype coverage. For example, in Sweden only 32 % of IPD cases in 2019 were caused by serotypes included in PCV13, while PPV23 covered 64 % of invasive isolates (56). A 15-valent PCV (PCV15) developed by Merck & Co, adds two additional serotypes: 22F and 33F, and immunogenicity of the shared serotypes were non-inferior to PCV13 in a phase 2 trial of healthy older adults (189). Further, a 20-valent PCV (PCV20) which is under development by Pfizer, adds seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) compared to PCV13. Immunogenicity of the new serotypes in PCV20 were similar to PPV23, and the remainder comparable to PCV13 in 60-64 years old adults (190), and this vaccine is currently in phase 3 clinical trials. While PCV15 is developed for use in both infants and adults, PCV20 is intended for protection of adults against IPD. The gap between PCV and PPV23 is obviously closing, but PPV23 will still confer the broadest serotype protection, 37 years after it licensure in 1983.

With higher valency PCVs, the prime-boost pneumococcal immunization (PCV+PPV23) will probably become outdated as a strategy for broader protection, which was the original intention with the recommendation (57). However, in immunosuppressed populations with impaired response to PCV, a PPV23 booster dose could have the potential to enhance immunogenicity, as our study suggested for cDMARD treated IRD patients. Whether improvement of immunogenicity leads to higher efficacy for prevention of IPD is unknown. It has been hypothesized that while a PCV booster stimulates and expands the memory B cell pool, a PPV23 booster may results in depletion of these cells (39). Future studies are needed to better understand the immunological differences with repeat conjugate versus PS vaccine doses in immunocompromised populations.

The main problem with PCVs is that they only confer protection against certain capsular PS types. The optimal pneumococcal vaccine should be serotype independent, which principally could be achieved with a cross protective protein antigen, or a combination of protein antigens. Several pneumococcal protein antigen, e.g. virulence factors pneumococcal surface protein A, C, and pneumolysin have been studied in animal and to some extent in human models (65). Perhaps a more promising vaccine platform for the future is the whole-cell pneumococcal vaccine (WCV), which was ironically also the first type of pneumococcal vaccines that were developed in the early 20th century. The WCVs can be produced at a low cost and express a wide range of surface pneumococcal protein antigens for serotype independent cross protection, and an inactivated WCV is currently in phase 1/2 clinical trials (191).

At the time of writing this dissertation, we are amidst a historic pandemic of the novel disease coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (192). SARS-COV-2 causes a wide spectrum of disease from mild or asymptomatic infection to acute respiratory distress syndrome and multiorgan failure (193). The pandemic has put millions of people under lockdown, and immense pressure on healthcare and intensive care units worldwide. The pandemic has led to significant advances in the science of vaccinology, with several vaccines against Covid-19 now licensed in USA and Europe, including messenger RNA based platforms. The restrictions imposed due to the pandemic has been associated with historically low incidences of seasonal influenza virus infection in many countries (194) and a large decline in the incidence rate of IPD was observed in the UK (195). Coinfection of Covid-19 and IPD is rare (195).

The antirheumatic treatment arsenal is continuously growing, improving control of inflammation, leading to remission and enhanced quality of life in IRD patients. Biological treatments aimed at targeting important disease mechanisms, may have more or less predictable adverse effects on the physiological functions of immune cells or cytokines. Some priorities for research and development in this field can be identified. First, there will be an ongoing need of studies addressing immunogenicity of pneumococcal vaccines in relation to new classes of antirheumatic drugs, e.g. Janus kinase (JAK) inhibitors in RA patients. The importance of vaccinations early in the course of IRD, ideally before initiation of immunosuppressive treatment, cannot be stressed enough. Second, efforts are needed to obtain more knowledge on the efficacy of pneumococcal vaccines. As discussed earlier, PCVs and PPV23 have principal differences in their abilities to elicit TD or TI immune responses, but it is not clear how this translates in terms of efficacy, i.e. protection against pneumococcal infections. Third, with the challenges in obtaining efficacy data for pneumococcal vaccines in these patient groups, better understanding of immunological correlates of protection and long-term immune memory is vital. Fourth, epidemiological surveillance of serotypes is important to gain knowledge regarding differences in the ability to cause IPD and to tackle issues with serotype replacement.

Tack

Jag är mycket tacksam och stolt över att ha fått genomföra detta avhandlingsarbete som inneburit en stor möjlighet till fördjupning och eftertanke, samt ett komplement till det kliniska arbetet som infektionsläkare. Många har på olika sätt stöttat mig längs vägen och på olika sätt bidragit vid tillkomsten av mina vetenskapliga arbeten, men jag vill rikta ett särskilt stort tack till följande personer:

Meliha C Kapetanovic, min huvudhandledare, som varit en mycket positiv och motiverande kraft för mig som doktorand. Du är alltid lättillgänglig och svarar snabbt på mina frågor med kloka synpunkter. Även om vi oftast befunnit oss i olika städer har jag aldrig upplevt det som något stort avstånd.

Bo Settergren, bihandledare, som bidragit med omfattande kunskaper och erfarenheter, och som outtröttligt uppmuntrat mig längs vägen med ett ständigt glatt humör. Utan din hjälp hade jag aldrig börjat forska.

Göran Jönsson, bihandledare. Jag är mycket tacksam för att du varit med och handlett mig och delat med dig av dina stora kunskaper inom infektionssjukdomar och immunologi.

Åsa Johansson, medförfattare, för din vägledning av mig som kliniker till en inblick i flödescytometrisk metod inom immunologin.

Åsa Pettersson, medförfattare, för att du tog emot mig på BMC och på ett föredömligt sätt introducerade mig till flödescytometri.

Lillemor Skattum, medförfattare, som hjälpt mig mycket med bedömningar av ELISA och opsonofagocytos.

Christina Hansson, biomedicinsk analytiker, som hjälpt oss och visat mig opsonofagocytos.

Charlotte Sværke Jørgensen, medförfattare, som varit mycket hjälpsam vid överföring och analys av prover vid Statens Serum Institut i Köpenhamn.

Tore Saxne och Pierre Geborek, medförfattare som kommit med kloka synpunkter och uppmuntrande ord.

Anders Bengtsson, medförfattare, som bidragit med hjälp vid planering och utformning av det femte arbetet och mycket kloka synpunkter kring presentation av resultatet.

Jag vill också tacka medförfattarna Jon Einarsson, Thomas Mandl, Johanna Nagel och Tor Olofsson för fint samarbete.

Sjuksköterskorna Elna Haglund, Eva-Karin Kristofersson, and Nina Svensson vid reumamottagningen i Lund, som möjliggjort detta arbete.

Undersköterska Rose-Marie Glans, sjuksköterskor Åsa Möllerstedt, Kerstin Ståhle och Cecilia Svensson vid infektionsmottagningen i Kristianstad för er fina hjälp med provtagning och vaccination av studiepatienter.

Staffan Banke, min chef som varit mycket positiv och stöttande i detta arbete. Ditt ledarskap har gjort stor skillnad, inte minst under pandemin.

Johan Fält, kollega vid infektionskliniken, som gett mig utrymme för forskning i schemat trots pågående coronaviruspandemi av historiska mått.

Jag vill också tacka min familj, först och främst min älskade fru, Aleksandra, som alltid stöttar mig, ser till att jag pausar och dricker en kopp kaffe, och står ut med mig trots många sena kvällar och helger av arbete.

Mina föräldrar som alltid finns där för mig när jag behöver er. Ni är fantastiska! Pappa har som kollega och erfaren forskare dessutom fungerat som ett bollplank för mig.

Elbetija, svärmor, som underlättat mycket för oss i familjen genom barnpassning m.m.

Mina älskade döttrar, Alice, Mira, Ella och Vera, ni ger mig den allra största glädjen i livet.

Siri, vår labradoodle, som alltid blir lika glad att se mig, hållit mig sällskap under skrivandet och drar med mig ut på promenader.

References

1. Leung AKC. “Variolation” and Vaccination in Late Imperial China, Ca 1570–1911. In: Plotkin SA, editor. History of vaccine development. New York: Springer; 2011. p. xiii, 349 p.
2. Baxby D. Edward Jenner’s Role in the Introduction of Smallpox Vaccine. In: Plotkin SA, editor. History of vaccine development. New York: Springer; 2011. p. xiii, 349 p.
3. Bazin H. Pasteur and the Birth of Vaccines Made in the Laboratory. In: Plotkin SA, editor. History of vaccine development. New York: Springer; 2011. p. xiii, 349 p.
4. Austrian R. Bacterial Polysaccharide Vaccines. In: Plotkin SA, editor. History of vaccine development. New York: Springer; 2011. p. xiii, 349 p.
5. Schiemann O, Casper W. Sind die spezifisch präcipitablen Substanzen der 3 Pneumokokkentypen Haptene? Medical Microbiology and Immunology. 1927;108(1):220-57.
6. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. Journal of Experimental Medicine. 1930;52(4):561-71.
7. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. Journal of Experimental Medicine. 1945;82(6):445-65.
8. Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983;148(6):1136-59.
9. Organization WH. Measles [Available from: <https://www.who.int/news-room/fact-sheets/detail/measles>].
10. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007;25(29):5390-8.
11. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3(7).
12. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis. 1997;24 Suppl 1:S85-8.
13. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849-59.

14. Greenwood D. Medical microbiology : a guide to microbial infections : pathogenesis, immunity, laboratory diagnosis and control. 18th ed. Edinburgh: Churchill Livingstone Elsevier; 2012. xvi, 778 p. p.
15. Bennett JE, Dolin R, Mandell GL, Douglas RG. Streptococcus pneumoniae. Mandell, Douglas, and Bennett's principles and practice of infectious diseases Volume 1. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010. p. 2623-42.
16. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. *Clin Microbiol Rev.* 2015;28(3):871-99.
17. Keller LE, Robinson DA, McDaniel LS. Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. *MBio.* 2016;7(2):e01792.
18. Murray PR. Medical microbiology. 4th ed. St. Louis: Mosby; 2002. x, 826 p. p.
19. Musher DM, Chapman AJ, Gore A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. *J Infect Dis.* 1986;154(2):245-56.
20. Balmer P, Borrow R, Findlow J, Warrington R, Frankland S, Waight P, et al. Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. *Clin Vaccine Immunol.* 2007;14(11):1442-50.
21. Wara DW. Host defense against Streptococcus pneumoniae: the role of the spleen. *Rev Infect Dis.* 1981;3(2):299-309.
22. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet.* 2011;378(9785):86-97.
23. Grabenstein JD, Musher DM. Pneumococcal polysaccharide vaccines. *Plotkin's Vaccines: Elsevier;* 2018. p. 816-40. e13.
24. Advisory Committee on Immunization P. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2000;49(RR-9):1-35.
25. Pneumococcal disease: Centers for Disease Control and Prevention; [updated September 6, 2017. Available from: <https://www.cdc.gov/pneumococcal/surveillance.html>.
26. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. *Thorax.* 2015;70(10):984-9.
27. van Aalst M, Lotsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. *Travel Med Infect Dis.* 2018;24:89-100.
28. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. *J Epidemiol Community Health.* 2012;66(12):1177-81.

29. Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. *BMC Infect Dis.* 2016;16:367.
30. Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. *Clin Infect Dis.* 2016;62(2):139-47.
31. Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions. *Infect Drug Resist.* 2019;12:2839-51.
32. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. *J Clin Pathol.* 2001;54(3):214-8.
33. Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Plotkin's vaccines.* Seventh edition. ed. Philadelphia, PA: Elsevier; 2018. p. xxi, 1691 pages.
34. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med.* 1998;187(1):129-34.
35. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. *J Immunol.* 1995;155(12):5483-6.
36. Chemin K, Gerstner C, Malmstrom V. Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. *Front Immunol.* 2019;10:353.
37. Schaerli P, Willmann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J Exp Med.* 2000;192(11):1553-62.
38. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, et al. Extrafollicular antibody responses. *Immunol Rev.* 2003;194:8-18.
39. Papadatou I, Spoulou V. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right? *Clin Vaccine Immunol.* 2016;23(5):388-95.
40. Jacob J, Kassir R, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. *J Exp Med.* 1991;173(5):1165-75.
41. Webb LMC, Linterman MA. Signals that drive T follicular helper cell formation. *Immunology.* 2017;152(2):185-94.
42. Ise W, Kurosaki T. Plasma cell differentiation during the germinal center reaction. *Immunol Rev.* 2019;288(1):64-74.
43. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? *Clin Infect Dis.* 2011;52(5):633-40.
44. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. *Wkly Epidemiol Rec.* 2008;83(42):373-84.
45. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines. *Vaccine.* 2015;33 Suppl 4:D60-5.

46. Izumi Y, Akazawa M, Akeda Y, Tohma S, Hirano F, Ideguchi H, et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. *Arthritis Res Ther*. 2017;19(1):15.
47. Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis*. 2011;70(7):1289-91.
48. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*. 2015;372(12):1114-25.
49. Musher DM, Rodriguez-Barradas MC. The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries. *Hum Vaccin Immunother*. 2014;10(5):1331-3.
50. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev*. 2013(1):CD000422.
51. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *N Engl J Med*. 2010;362(9):812-22.
52. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet*. 2000;355(9221):2106-11.
53. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med*. 2003;348(18):1737-46.
54. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis*. 2010;201(1):32-41.
55. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. *Lancet Infect Dis*. 2018;18(4):441-51.
56. Folkhälsomyndigheten. Pneumokockinfektion - invasiv – sjukdomsstatistik — Folkhälsomyndigheten 2020 [Available from: <http://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/pneumokockinfektion-invasiv/>].
57. Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. 2012;61(40):816-9.
58. Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Esmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <https://doi.org/10.1080/2164551520161150396>. 2016.

59. Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *AIDS*. 2007;21(18):2425-34.
60. Sadlier C, O'Dea S, Bennett K, Dunne J, Conlon N, Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. *Sci Rep*. 2016;6:32076.
61. Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. *Clin Infect Dis*. 2008;47(7):885-92.
62. Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. *PLoS One*. 2012;7(9):e46133.
63. Nguyen MTT, Lindegaard H, Hendricks O, Jorgensen CS, Kantso B, Friis-Moller N. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial. *J Rheumatol*. 2017;44(12):1794-803.
64. Organization WH. The WHO consensus pneumococcal IgG ELISA. Training manual for enzyme-linked immunosorbent assay for the quantitation of *Streptococcus pneumoniae* serotype-specific IgG (Pn PS ELISA): a guide to procedures for qualification of materials and analysis of assay performance. 2017 [Available from: [https://www.vaccine.uab.edu/ELISAProtocol\(007sp\).pdf](https://www.vaccine.uab.edu/ELISAProtocol(007sp).pdf)].
65. Klugman KP, Dagan R, Malley R, Whitney CG. 46 - Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. *Plotkin's Vaccines (Seventh Edition)*: Elsevier; 2018. p. 773-815.e18.
66. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against *Streptococcus pneumoniae* using differentiated HL-60 cells. *Clin Diagn Lab Immunol*. 1997;4(4):415-22.
67. Martinez JE, Romero-Steiner S, Pilishvili T, Barnard S, Schinsky J, Goldblatt D, et al. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. *Clin Diagn Lab Immunol*. 1999;6(4):581-6.
68. Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. *Vaccine*. 2003;21(23):3265-72.
69. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2012;130(3 Suppl):S1-24.

70. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infect Dis.* 2014;14(9):839-46.
71. Nagel J, Geborek P, Saxne T, Jonsson G, Englund M, Petersson IF, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. *Scand J Rheumatol.* 2015;44(4):271-9.
72. Sorensen RU, Leiva LE, Javier FC, 3rd, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to *Streptococcus pneumoniae* vaccine in patients with recurrent infections and normal immunoglobulin concentrations. *J Allergy Clin Immunol.* 1998;102(2):215-21.
73. Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. *J Allergy Clin Immunol.* 2009;123(1):195-200.
74. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. *Arthritis Rheum.* 2010;62(6):1576-82.
75. Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. *J Autoimmun.* 2010;35(1):10-4.
76. Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Bossuyt X, Verschueren P, Westhovens R. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo--a population-based study. *Rheumatology (Oxford).* 2012;51(9):1644-7.
77. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. *Semin Arthritis Rheum.* 1999;28(6):368-91.
78. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31(3):315-24.
79. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010;62(9):2569-81.
80. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995;38(1):44-8.
81. Thomas R, McIlraith M, Davis LS, Lipsky PE. Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. *Arthritis Rheum.* 1992;35(12):1455-65.
82. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med.* 2003;349(20):1907-15.
83. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007;447(7145):661-78.

84. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987;30(11):1205-13.
85. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Primers.* 2018;4:18001.
86. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med.* 2007;146(11):797-808.
87. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. *Clin Exp Rheumatol.* 1999;17(6):689-97.
88. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum.* 2006;54(9):2793-806.
89. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. *Arthritis Res Ther.* 2009;11(3):R84.
90. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. *Best Pract Res Clin Rheumatol.* 2001;15(5):677-91.
91. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. *Nat Rev Immunol.* 2002;2(5):364-71.
92. Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. *Drug Des Devel Ther.* 2016;10:2069-80.
93. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? *Ann Rheum Dis.* 2018;77(2):175-87.
94. Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. *Immunity.* 2011;34(6):961-72.
95. Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. *Trends Immunol.* 2014;35(9):436-42.
96. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. *Immunity.* 2011;34(1):108-21.
97. Arroyo-Villa I, Bautista-Caro MB, Balsa A, Aguado-Acin P, Bonilla-Hernan MG, Plasencia C, et al. Constitutively altered frequencies of circulating follicular helper T cell counterparts and their subsets in rheumatoid arthritis. *Arthritis Res Ther.* 2014;16(6):500.

98. Zhang Y, Li Y, Lv TT, Yin ZJ, Wang XB. Elevated circulating Th17 and follicular helper CD4(+) T cells in patients with rheumatoid arthritis. *APMIS*. 2015;123(8):659-66.
99. Nakayamada S, Tanaka Y. T follicular helper (Tfh) cells in autoimmune diseases. *Nihon Rinsho Meneki Gakkai Kaishi*. 2016;39(1):1-7.
100. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. *Clin Exp Immunol*. 2013;174(2):212-20.
101. Chakera A, Bennett SC, Morteau O, Bowness P, Luqmani RA, Cornall RJ. The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target. *Clin Dev Immunol*. 2012;2012:948218.
102. Costantino AB, Acosta CDV, Onetti L, Mussano E, Cadile, II, Ferrero PV. Follicular helper T cells in peripheral blood of patients with rheumatoid arthritis. *Reumatol Clin*. 2017;13(6):338-43.
103. Penatti A, Facciotti F, De Matteis R, Larghi P, Paroni M, Murgo A, et al. Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther*. 2017;19(1):103.
104. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol*. 1995;155(3):1151-64.
105. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, Jackson SE, et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. *J Immunol*. 2010;184(8):4317-26.
106. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. *J Exp Med*. 2004;200(3):277-85.
107. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013;65(1):1-11.
108. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis*. 2007;66(2):222-7.
109. ACR Endorsed Criteria 2020 [Available from: <https://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria>].
110. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis*. 2017;76(1):9-16.

111. Stahn C, Buttgerit F. Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol.* 2008;4(10):525-33.
112. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. *J Allergy Clin Immunol.* 2010;125(2 Suppl 2):S195-203.
113. Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. *BMJ.* 2020;368:m421.
114. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol.* 2016;12(12):731-42.
115. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. *J Pharm Sci.* 1989;78(2):165-71.
116. Saxne T, Klareskog L, Enman Y. *Reumatologi.* Lettland.
117. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. *Cochrane Database Syst Rev.* 2014(6):CD000957.
118. Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. *Nat Rev Rheumatol.* 2020;16(3):145-54.
119. Cronstein BN, Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. *Nat Rev Rheumatol.* 2017;13(1):41-51.
120. Bitoun S, Nocturne G, Ly B, Krzysiek R, Roques P, Pruvost A, et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. *Ann Rheum Dis.* 2018;77(10):1463-70.
121. Koukoulaki M, Iatrou C. The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis. *World J Nephrol.* 2019;8(4):75-82.
122. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med.* 2005;353(11):1114-23.
123. Cutolo M, Sulli A, Paolino S, Pizzorni C. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. *Expert Rev Clin Immunol.* 2016;12(4):417-25.
124. Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. *J Rheumatol.* 2014;41(4):666-72.
125. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med.* 2010;363(3):221-32.
126. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med.* 2010;363(3):211-20.
127. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. *J Immunol.* 2009;182(10):5982-93.

128. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. *Arthritis Rheum.* 2007;56(9):3044-56.
129. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. *Nat Clin Pract Rheumatol.* 2007;3(2):86-95.
130. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatology (Oxford).* 2013;52(1):53-61.
131. Starkebaum G. Chronic neutropenia associated with autoimmune disease. *Semin Hematol.* 2002;39(2):121-7.
132. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. *Proc Natl Acad Sci U S A.* 1998;95(24):14447-52.
133. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. *Proc Natl Acad Sci U S A.* 2000;97(16):9203-8.
134. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum.* 2002;46(9):2287-93.
135. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. *Arthritis Rheum.* 2002;46(9):2294-300.
136. George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. *Ann Intern Med.* 2020.
137. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc.* 1996;71(1):5-13.
138. Lacaillle D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum.* 2008;59(8):1074-81.
139. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol.* 2003;30(7):1436-9.
140. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum.* 2005;52(7):1986-92.
141. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). *Ann Rheum Dis.* 2010;69(3):522-8.
142. Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. *Arthritis Care Res (Hoboken).* 2018;70(5):724-31.

143. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. *Lancet*. 2015;386(9990):258-65.
144. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. *Ann Rheum Dis*. 2009;68(1):25-32.
145. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. *Arthritis Rheum*. 2007;56(12):3896-908.
146. van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. *J Rheumatol*. 2010;37(3):558-67.
147. Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2018;57(6):997-1001.
148. Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. *Arthritis Res Ther*. 2012;14(2):210.
149. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis*. 2011;70(3):488-94.
150. McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. *Nephrol Dial Transplant*. 2015;30 Suppl 1:i171-81.
151. Goupil R, Brachemi S, Nadeau-Fredette AC, Deziel C, Troyanov Y, Lavergne V, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. *Clin J Am Soc Nephrol*. 2013;8(3):416-23.
152. Waki D, Nishimura K, Tokumasu H, Kadoba K, Mukoyama H, Saito R, et al. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. *Medicine (Baltimore)*. 2020;99(8):e19173.
153. Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study. *Arthritis Rheumatol*. 2016;68(6):1477-82.
154. Brito-Zeron P, Kostov B, Solans R, Fraile G, Suarez-Cuervo C, Casanovas A, et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. *Ann Rheum Dis*. 2016;75(2):348-55.

155. Chang YS, Liu CJ, Ou SM, Hu YW, Chen TJ, Lee HT, et al. Tuberculosis infection in primary Sjogren's syndrome: a nationwide population-based study. *Clin Rheumatol*. 2014;33(3):377-83.
156. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. *Ann Rheum Dis*. 2013;72(8):1362-6.
157. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Ann Rheum Dis*. 2016;75(4):687-95.
158. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. *Arthritis Rheum*. 2011;63(12):3723-32.
159. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2006;45(1):106-11.
160. Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Morner A, Geborek P. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. *Arthritis Res Ther*. 2014;16(1):R2.
161. Kapetanovic MC, Nagel J, Nordstrom I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. *Vaccine*. 2017;35(6):903-8.
162. Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2013;15(5):R171.
163. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. *Arthritis Res Ther*. 2015;17:357.
164. Bingham CO, 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum*. 2010;62(1):64-74.
165. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. *Arthritis Res Ther*. 2010;12(3):R111.
166. Nived P, Nagel J, Saxne T, Geborek P, Jonsson G, Skattum L, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. *Vaccine*. 2017;35(29):3639-46.

167. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine *Streptococcus pneumoniae* serotypes. *J Immunol Methods*. 2005;296(1-2):135-47.
168. Schlottmann SA, Jain N, Chirmule N, Esser MT. A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres. *J Immunol Methods*. 2006;309(1-2):75-85.
169. Quataert SA, Rittenhouse-Olson K, Kirch CS, Hu B, Secor S, Strong N, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). *Clin Diagn Lab Immunol*. 2004;11(6):1064-9.
170. Jonsson G, Lood C, Gullstrand B, Holmstrom E, Selander B, Braconier JH, et al. Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. *Clin Immunol*. 2012;144(3):214-27.
171. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. *Nat Rev Immunol*. 2012;12(3):191-200.
172. Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, et al. A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. *Mech Ageing Dev*. 2009;130(10):681-90.
173. Coignard-Biehler H, Lanternier F, Hot A, Salmon D, Berger A, de Montalembert M, et al. Adherence to preventive measures after splenectomy in the hospital setting and in the community. *J Infect Public Health*. 2011;4(4):187-94.
174. Lammers AJ, Veninga D, Lombarts MJ, Hoekstra JB, Speelman P. Management of post-splenectomy patients in the Netherlands. *Eur J Clin Microbiol Infect Dis*. 2010;29(4):399-405.
175. Stanford E, Print F, Falconer M, Lamden K, Ghebrehewet S, Phin N, et al. Immune response to pneumococcal conjugate vaccination in asplenic individuals. *Hum Vaccin*. 2009;5(2):85-91.
176. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. *Clin Infect Dis*. 2008;46(7):1015-23.
177. Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. *Clin Infect Dis*. 2011;52(6):736-42.
178. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. *Vaccine*. 2014;32(20):2364-74.
179. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. *Vaccine*. 2013;31(35):3594-602.

180. David Morgan M, Richter A, Al-Ali S, Flint J, Yiannakis C, Drayson M, et al. Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. *Arthritis Care Res (Hoboken)*. 2016;68(6):853-60.
181. Groh M, Puechal X, Terrier B, Le Jeune C, Batteux F, Launay O. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study. *Joint Bone Spine*. 2017;84(5):643-4.
182. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)*. 2014;66(7):1016-26.
183. Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. *J Infect Dis*. 2004;190(3):545-50.
184. Romero-Steiner S, Frasci CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Clin Vaccine Immunol*. 2006;13(2):165-9.
185. Szalay B, Vasarhelyi B, Cseh A, Tulassay T, Deak M, Kovacs L, et al. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. *Clin Rheumatol*. 2014;33(2):175-85.
186. Guggino G, Giardina A, Ferrante A, Giardina G, Schinocca C, Sireci G, et al. The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis. *Rheumatol Int*. 2015;35(1):171-5.
187. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. *Arthritis Rheum*. 2009;60(6):1647-56.
188. Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. *Semin Immunopathol*. 2010;32(1):79-90.
189. Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. *Hum Vaccin Immunother*. 2019;15(3):530-9.
190. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. *Clin Infect Dis*. 2020.
191. Morais V, Texeira E, Suarez N. Next-Generation Whole-Cell Pneumococcal Vaccine. *Vaccines (Basel)*. 2019;7(4).
192. WHO announces COVID-19 outbreak a pandemic: World Health Organization; 2020 [updated 2020-03-12. Available from: <https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>.

193. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-42.
194. Jones N. How COVID-19 is changing the cold and flu season. *Nature*. 2020;588(7838):388-90.
195. Amin-Chowdhury Z, Aiano F, Mensah A, Sheppard CL, Litt D, Fry NK, et al. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England. *Clin Infect Dis*. 2021;72(5):e65-e75.



**FACULTY OF
MEDICINE**

Section of Rheumatology
Department of Clinical Sciences Lund

Lund University, Faculty of Medicine
Doctoral Dissertation Series 2020:36
ISBN 978-91-8021-042-3
ISSN 1652-8220

